MX2008001230A - Microarray device - Google Patents
Microarray deviceInfo
- Publication number
- MX2008001230A MX2008001230A MXMX/A/2008/001230A MX2008001230A MX2008001230A MX 2008001230 A MX2008001230 A MX 2008001230A MX 2008001230 A MX2008001230 A MX 2008001230A MX 2008001230 A MX2008001230 A MX 2008001230A
- Authority
- MX
- Mexico
- Prior art keywords
- microneedle
- nanoparticle
- group
- microneedles
- nanoparticles
- Prior art date
Links
- 238000002493 microarray Methods 0.000 title description 6
- 239000002105 nanoparticle Substances 0.000 claims abstract description 138
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 49
- 239000003814 drug Substances 0.000 claims abstract description 36
- 238000004519 manufacturing process Methods 0.000 claims abstract description 24
- -1 for example Substances 0.000 claims abstract description 17
- 229920000642 polymer Polymers 0.000 claims description 56
- 239000000203 mixture Substances 0.000 claims description 36
- 239000000463 material Substances 0.000 claims description 33
- 102000004169 proteins and genes Human genes 0.000 claims description 30
- 108090000623 proteins and genes Proteins 0.000 claims description 30
- 229960005486 vaccines Drugs 0.000 claims description 30
- 201000010099 disease Diseases 0.000 claims description 29
- 229920001940 conductive polymer Polymers 0.000 claims description 22
- 210000001519 tissues Anatomy 0.000 claims description 22
- 239000004020 conductor Substances 0.000 claims description 19
- 241000283690 Bos taurus Species 0.000 claims description 17
- 239000011148 porous material Substances 0.000 claims description 17
- 125000000524 functional group Chemical group 0.000 claims description 15
- 239000011248 coating agent Substances 0.000 claims description 14
- 238000000576 coating method Methods 0.000 claims description 14
- 239000002245 particle Substances 0.000 claims description 13
- 239000000126 substance Substances 0.000 claims description 13
- 150000001875 compounds Chemical class 0.000 claims description 11
- 229920000128 polypyrrole Polymers 0.000 claims description 11
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 11
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 11
- 208000004396 Mastitis Diseases 0.000 claims description 10
- 238000000465 moulding Methods 0.000 claims description 10
- 229920000767 polyaniline Polymers 0.000 claims description 10
- 230000003993 interaction Effects 0.000 claims description 9
- 229910052751 metal Inorganic materials 0.000 claims description 9
- 239000002184 metal Substances 0.000 claims description 9
- WOBHKFSMXKNTIM-UHFFFAOYSA-N 2-hydroxyethyl 2-methylacrylate Chemical compound CC(=C)C(=O)OCCO WOBHKFSMXKNTIM-UHFFFAOYSA-N 0.000 claims description 8
- VVQNEPGJFQJSBK-UHFFFAOYSA-N 2-methyl-2-propenoic acid methyl ester Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 claims description 8
- 239000003124 biologic agent Substances 0.000 claims description 7
- 230000002209 hydrophobic Effects 0.000 claims description 7
- 150000002739 metals Chemical class 0.000 claims description 7
- 238000004070 electrodeposition Methods 0.000 claims description 6
- 239000011521 glass Substances 0.000 claims description 6
- 125000000520 N-substituted aminocarbonyl group Chemical group [*]NC(=O)* 0.000 claims description 5
- 239000004696 Poly ether ether ketone Substances 0.000 claims description 5
- 238000006065 biodegradation reaction Methods 0.000 claims description 5
- 239000002041 carbon nanotube Substances 0.000 claims description 5
- 229910021393 carbon nanotube Inorganic materials 0.000 claims description 5
- 239000002082 metal nanoparticle Substances 0.000 claims description 5
- 229920002530 poly[4-(4-benzoylphenoxy)phenol] polymer Polymers 0.000 claims description 5
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 5
- 239000007787 solid Substances 0.000 claims description 5
- 229960000633 Dextran Sulfate Drugs 0.000 claims description 4
- 229950003499 FIBRIN Drugs 0.000 claims description 4
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 claims description 4
- 102000009123 Fibrin Human genes 0.000 claims description 4
- 108010073385 Fibrin Proteins 0.000 claims description 4
- JVTAAEKCZFNVCJ-REOHCLBHSA-N L-lactic acid Chemical compound C[C@H](O)C(O)=O JVTAAEKCZFNVCJ-REOHCLBHSA-N 0.000 claims description 4
- 229920000272 Oligonucleotide Polymers 0.000 claims description 4
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 4
- 229920000954 Polyglycolide Polymers 0.000 claims description 4
- 239000004793 Polystyrene Substances 0.000 claims description 4
- 238000004458 analytical method Methods 0.000 claims description 4
- 239000000969 carrier Substances 0.000 claims description 4
- 239000002131 composite material Substances 0.000 claims description 4
- 230000001809 detectable Effects 0.000 claims description 4
- 239000000032 diagnostic agent Substances 0.000 claims description 4
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 claims description 4
- 229910052737 gold Inorganic materials 0.000 claims description 4
- 239000010931 gold Substances 0.000 claims description 4
- 230000001939 inductive effect Effects 0.000 claims description 4
- PXHVJJICTQNCMI-UHFFFAOYSA-N nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 claims description 4
- 150000007523 nucleic acids Chemical class 0.000 claims description 4
- 108020004707 nucleic acids Proteins 0.000 claims description 4
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 claims description 4
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims description 4
- 229920000747 poly(lactic acid) polymer Polymers 0.000 claims description 4
- 229920000768 polyamine Polymers 0.000 claims description 4
- 229920001707 polybutylene terephthalate Polymers 0.000 claims description 4
- 229920001610 polycaprolactone Polymers 0.000 claims description 4
- 239000004632 polycaprolactone Substances 0.000 claims description 4
- 229920000120 polyethyl acrylate Polymers 0.000 claims description 4
- 229920000139 polyethylene terephthalate Polymers 0.000 claims description 4
- 239000005020 polyethylene terephthalate Substances 0.000 claims description 4
- 239000004633 polyglycolic acid Substances 0.000 claims description 4
- 239000004626 polylactic acid Substances 0.000 claims description 4
- 229920001296 polysiloxane Polymers 0.000 claims description 4
- 229920002223 polystyrene Polymers 0.000 claims description 4
- 229920002635 polyurethane Polymers 0.000 claims description 4
- 239000004814 polyurethane Substances 0.000 claims description 4
- 238000006722 reduction reaction Methods 0.000 claims description 4
- 229920000936 Agarose Polymers 0.000 claims description 3
- 241001272720 Medialuna californiensis Species 0.000 claims description 3
- 229920001609 Poly(3,4-ethylenedioxythiophene) Polymers 0.000 claims description 3
- 229910003460 diamond Inorganic materials 0.000 claims description 3
- 239000010432 diamond Substances 0.000 claims description 3
- 239000001257 hydrogen Substances 0.000 claims description 3
- 229910052739 hydrogen Inorganic materials 0.000 claims description 3
- 239000004065 semiconductor Substances 0.000 claims description 3
- 229910052709 silver Inorganic materials 0.000 claims description 3
- 239000004332 silver Substances 0.000 claims description 3
- BQCADISMDOOEFD-UHFFFAOYSA-N silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 claims description 3
- RTAQQCXQSZGOHL-UHFFFAOYSA-N titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 claims description 3
- 229910052719 titanium Inorganic materials 0.000 claims description 3
- 239000010936 titanium Substances 0.000 claims description 3
- 229920000160 (ribonucleotides)n+m Polymers 0.000 claims description 2
- JJJFUHOGVZWXNQ-UHFFFAOYSA-N Butyl cyanoacrylate Chemical compound CCCCOC(=O)C(=C)C#N JJJFUHOGVZWXNQ-UHFFFAOYSA-N 0.000 claims description 2
- 229920001651 Cyanoacrylate Polymers 0.000 claims description 2
- 210000002381 Plasma Anatomy 0.000 claims description 2
- 229920001710 Polyorthoester Polymers 0.000 claims description 2
- 239000000560 biocompatible material Substances 0.000 claims description 2
- 150000001720 carbohydrates Chemical class 0.000 claims description 2
- 235000014633 carbohydrates Nutrition 0.000 claims description 2
- 239000000919 ceramic Substances 0.000 claims description 2
- 229920001577 copolymer Polymers 0.000 claims description 2
- 229910052802 copper Inorganic materials 0.000 claims description 2
- RYGMFSIKBFXOCR-UHFFFAOYSA-N copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims description 2
- 239000010949 copper Substances 0.000 claims description 2
- 238000004132 cross linking Methods 0.000 claims description 2
- 229920003013 deoxyribonucleic acid Polymers 0.000 claims description 2
- 229950010048 enbucrilate Drugs 0.000 claims description 2
- 238000010438 heat treatment Methods 0.000 claims description 2
- 239000000017 hydrogel Substances 0.000 claims description 2
- 229920000592 inorganic polymer Polymers 0.000 claims description 2
- 238000003780 insertion Methods 0.000 claims description 2
- 238000002386 leaching Methods 0.000 claims description 2
- 150000002632 lipids Chemical class 0.000 claims description 2
- 239000007769 metal material Substances 0.000 claims description 2
- 239000011859 microparticle Substances 0.000 claims description 2
- 229920005615 natural polymer Polymers 0.000 claims description 2
- 229910052759 nickel Inorganic materials 0.000 claims description 2
- 229920000620 organic polymer Polymers 0.000 claims description 2
- 230000003647 oxidation Effects 0.000 claims description 2
- 238000007254 oxidation reaction Methods 0.000 claims description 2
- 229910052763 palladium Inorganic materials 0.000 claims description 2
- 229910052697 platinum Inorganic materials 0.000 claims description 2
- 239000002745 poly(ortho ester) Substances 0.000 claims description 2
- 229920005591 polysilicon Polymers 0.000 claims description 2
- 150000003377 silicon compounds Chemical class 0.000 claims description 2
- 238000006467 substitution reaction Methods 0.000 claims description 2
- 229920001059 synthetic polymer Polymers 0.000 claims description 2
- 229920001169 thermoplastic Polymers 0.000 claims description 2
- 210000003491 Skin Anatomy 0.000 abstract description 15
- 210000002615 Epidermis Anatomy 0.000 abstract description 3
- 210000000929 Nociceptors Anatomy 0.000 abstract 1
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 54
- 108090001061 Insulin Proteins 0.000 description 27
- 102000004877 Insulin Human genes 0.000 description 27
- 229940079593 drugs Drugs 0.000 description 25
- 238000000034 method Methods 0.000 description 17
- 102000038129 antigens Human genes 0.000 description 16
- 108091007172 antigens Proteins 0.000 description 16
- 210000004027 cells Anatomy 0.000 description 16
- 239000000427 antigen Substances 0.000 description 15
- 239000003153 chemical reaction reagent Substances 0.000 description 15
- 239000002096 quantum dot Substances 0.000 description 15
- 210000000434 stratum corneum Anatomy 0.000 description 13
- 229920000515 polycarbonate Polymers 0.000 description 10
- 239000004417 polycarbonate Substances 0.000 description 10
- 108090001123 antibodies Proteins 0.000 description 9
- 102000004965 antibodies Human genes 0.000 description 9
- 230000015572 biosynthetic process Effects 0.000 description 9
- 238000005755 formation reaction Methods 0.000 description 9
- 239000004205 dimethyl polysiloxane Substances 0.000 description 8
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 8
- 230000001225 therapeutic Effects 0.000 description 8
- 241000700605 Viruses Species 0.000 description 6
- 201000009910 diseases by infectious agent Diseases 0.000 description 6
- 238000002255 vaccination Methods 0.000 description 6
- 241000894006 Bacteria Species 0.000 description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N D-Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
- 102000003951 Erythropoietin Human genes 0.000 description 5
- 108090000394 Erythropoietin Proteins 0.000 description 5
- 239000002671 adjuvant Substances 0.000 description 5
- 230000000240 adjuvant Effects 0.000 description 5
- 230000035492 administration Effects 0.000 description 5
- 229940105423 erythropoietin Drugs 0.000 description 5
- 239000008103 glucose Substances 0.000 description 5
- 150000004676 glycans Polymers 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 229920001282 polysaccharide Polymers 0.000 description 5
- 239000005017 polysaccharide Substances 0.000 description 5
- 150000004804 polysaccharides Polymers 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 201000008827 tuberculosis Diseases 0.000 description 5
- 210000004369 Blood Anatomy 0.000 description 4
- 229940088597 Hormone Drugs 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 238000004624 confocal microscopy Methods 0.000 description 4
- 235000013365 dairy product Nutrition 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 239000005556 hormone Substances 0.000 description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 4
- 230000003053 immunization Effects 0.000 description 4
- 238000002649 immunization Methods 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- 238000000608 laser ablation Methods 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 210000003743 Erythrocytes Anatomy 0.000 description 3
- 241000242711 Fasciola hepatica Species 0.000 description 3
- 208000006275 Fascioliasis Diseases 0.000 description 3
- 102000018997 Growth Hormone Human genes 0.000 description 3
- 108010051696 Growth Hormone Proteins 0.000 description 3
- 241000711549 Hepacivirus C Species 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 241000186359 Mycobacterium Species 0.000 description 3
- 241000283898 Ovis Species 0.000 description 3
- 102000003982 Parathyroid hormone Human genes 0.000 description 3
- 108090000445 Parathyroid hormone Proteins 0.000 description 3
- 210000002966 Serum Anatomy 0.000 description 3
- 241000194054 Streptococcus uberis Species 0.000 description 3
- 238000002679 ablation Methods 0.000 description 3
- 239000002246 antineoplastic agent Substances 0.000 description 3
- 230000002238 attenuated Effects 0.000 description 3
- 230000001580 bacterial Effects 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 230000001413 cellular Effects 0.000 description 3
- 230000004059 degradation Effects 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 239000003527 fibrinolytic agent Substances 0.000 description 3
- 239000000122 growth hormone Substances 0.000 description 3
- 239000003018 immunosuppressive agent Substances 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 229960001319 parathyroid hormone Drugs 0.000 description 3
- 239000000199 parathyroid hormone Substances 0.000 description 3
- 230000035515 penetration Effects 0.000 description 3
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 150000003180 prostaglandins Chemical class 0.000 description 3
- 238000001878 scanning electron micrograph Methods 0.000 description 3
- 150000003384 small molecules Chemical class 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 230000002588 toxic Effects 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- VZCYOOQTPOCHFL-OWOJBTEDSA-N (E)-but-2-enedioate;hydron Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 229930000680 A04AD01 - Scopolamine Natural products 0.000 description 2
- 229940035676 ANALGESICS Drugs 0.000 description 2
- 229940035674 ANESTHETICS Drugs 0.000 description 2
- WNLRTRBMVRJNCN-UHFFFAOYSA-N Adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 2
- 229940064005 Antibiotic throat preparations Drugs 0.000 description 2
- 229940083879 Antibiotics FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE Drugs 0.000 description 2
- 229940042052 Antibiotics for systemic use Drugs 0.000 description 2
- 229940042786 Antitubercular Antibiotics Drugs 0.000 description 2
- 230000035639 Blood Levels Effects 0.000 description 2
- 210000004204 Blood Vessels Anatomy 0.000 description 2
- 229940098773 Bovine Serum Albumin Drugs 0.000 description 2
- 108091003117 Bovine Serum Albumin Proteins 0.000 description 2
- AQCDIIAORKRFCD-UHFFFAOYSA-N Cadmium selenide Chemical compound [Cd]=[Se] AQCDIIAORKRFCD-UHFFFAOYSA-N 0.000 description 2
- 102000004172 Cathepsin L Human genes 0.000 description 2
- 108090000624 Cathepsin L Proteins 0.000 description 2
- 210000000170 Cell Membrane Anatomy 0.000 description 2
- 210000002421 Cell Wall Anatomy 0.000 description 2
- 206010013023 Diphtheria Diseases 0.000 description 2
- 102000030807 Fatty Acid-Binding Proteins Human genes 0.000 description 2
- 108091022018 Fatty Acid-Binding Proteins Proteins 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 210000001035 Gastrointestinal Tract Anatomy 0.000 description 2
- 102000005720 Glutathione Transferase family Human genes 0.000 description 2
- 108010070675 Glutathione Transferase family Proteins 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- 229940093922 Gynecological Antibiotics Drugs 0.000 description 2
- 101700042506 HIRUD Proteins 0.000 description 2
- 208000006454 Hepatitis Diseases 0.000 description 2
- 229940006607 Hirudin Drugs 0.000 description 2
- 208000006572 Human Influenza Diseases 0.000 description 2
- STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 description 2
- 206010022000 Influenza Diseases 0.000 description 2
- 210000004185 Liver Anatomy 0.000 description 2
- 229940040129 Luteinizing Hormone Drugs 0.000 description 2
- 102000009151 Luteinizing Hormone Human genes 0.000 description 2
- 108010073521 Luteinizing Hormone Proteins 0.000 description 2
- 210000001365 Lymphatic Vessels Anatomy 0.000 description 2
- 229920002521 Macromolecule Polymers 0.000 description 2
- 210000004080 Milk Anatomy 0.000 description 2
- 208000005647 Mumps Diseases 0.000 description 2
- SNICXCGAKADSCV-JTQLQIEISA-N Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 2
- 229960002715 Nicotine Drugs 0.000 description 2
- 229940092253 Ovalbumin Drugs 0.000 description 2
- 108010058846 Ovalbumin Proteins 0.000 description 2
- WLJVNTCWHIRURA-UHFFFAOYSA-N Pimelic acid Chemical compound OC(=O)CCCCCC(O)=O WLJVNTCWHIRURA-UHFFFAOYSA-N 0.000 description 2
- 229940082622 Prostaglandin cardiac therapy preparations Drugs 0.000 description 2
- 229940077717 Prostaglandin drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) Drugs 0.000 description 2
- 210000003324 RBC Anatomy 0.000 description 2
- 206010037742 Rabies Diseases 0.000 description 2
- 241000702670 Rotavirus Species 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 241000607142 Salmonella Species 0.000 description 2
- 206010039447 Salmonellosis Diseases 0.000 description 2
- STECJAGHUSJQJN-FWXGHANASA-N Scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 description 2
- CXMXRPHRNRROMY-UHFFFAOYSA-N Sebacic acid Chemical compound OC(=O)CCCCCCCCC(O)=O CXMXRPHRNRROMY-UHFFFAOYSA-N 0.000 description 2
- 241000194017 Streptococcus Species 0.000 description 2
- 229940115922 Streptococcus uberis Drugs 0.000 description 2
- 229940024982 Topical Antifungal Antibiotics Drugs 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000003444 anaesthetic Effects 0.000 description 2
- 230000000202 analgesic Effects 0.000 description 2
- 150000001450 anions Chemical class 0.000 description 2
- 230000003042 antagnostic Effects 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 239000000730 antalgic agent Substances 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 230000003110 anti-inflammatory Effects 0.000 description 2
- 239000002260 anti-inflammatory agent Substances 0.000 description 2
- 230000000692 anti-sense Effects 0.000 description 2
- 230000000890 antigenic Effects 0.000 description 2
- 239000003443 antiviral agent Substances 0.000 description 2
- 230000003115 biocidal Effects 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 239000000812 cholinergic antagonist Substances 0.000 description 2
- 230000001684 chronic Effects 0.000 description 2
- 230000003247 decreasing Effects 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 229920001971 elastomer Polymers 0.000 description 2
- 239000000806 elastomer Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000002496 gastric Effects 0.000 description 2
- 239000003193 general anesthetic agent Substances 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- 230000002440 hepatic Effects 0.000 description 2
- 231100000283 hepatitis Toxicity 0.000 description 2
- 230000002458 infectious Effects 0.000 description 2
- 229940079866 intestinal antibiotics Drugs 0.000 description 2
- 238000011068 load Methods 0.000 description 2
- 201000005505 measles Diseases 0.000 description 2
- 235000013372 meat Nutrition 0.000 description 2
- 230000001404 mediated Effects 0.000 description 2
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000006011 modification reaction Methods 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 229930015196 nicotine Natural products 0.000 description 2
- 229940005935 ophthalmologic Antibiotics Drugs 0.000 description 2
- 230000003287 optical Effects 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 229940094443 oxytocics Prostaglandins Drugs 0.000 description 2
- 230000000149 penetrating Effects 0.000 description 2
- 238000006116 polymerization reaction Methods 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 230000000241 respiratory Effects 0.000 description 2
- 201000005404 rubella Diseases 0.000 description 2
- 229960002646 scopolamine Drugs 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 238000000527 sonication Methods 0.000 description 2
- 229910052950 sphalerite Inorganic materials 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 230000000261 vasodilator Effects 0.000 description 2
- 239000003071 vasodilator agent Substances 0.000 description 2
- 229910052984 zinc sulfide Inorganic materials 0.000 description 2
- SNIOPGDIGTZGOP-UHFFFAOYSA-N 1,2,3-propanetrioltrinitrate Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 1
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1H-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 description 1
- WMRCTEPOPAZMMN-UHFFFAOYSA-N 2-undecylpropanedioic acid Chemical compound CCCCCCCCCCCC(C(O)=O)C(O)=O WMRCTEPOPAZMMN-UHFFFAOYSA-N 0.000 description 1
- LFEWXDOYPCWFHR-UHFFFAOYSA-N 4-(4-carboxybenzoyl)benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1C(=O)C1=CC=C(C(O)=O)C=C1 LFEWXDOYPCWFHR-UHFFFAOYSA-N 0.000 description 1
- NEQFBGHQPUXOFH-UHFFFAOYSA-N 4-(4-carboxyphenyl)benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1C1=CC=C(C(O)=O)C=C1 NEQFBGHQPUXOFH-UHFFFAOYSA-N 0.000 description 1
- ZDVJGWXFXGJSIU-UHFFFAOYSA-N 5-methylhexan-2-ol Chemical compound CC(C)CCC(C)O ZDVJGWXFXGJSIU-UHFFFAOYSA-N 0.000 description 1
- 239000005541 ACE inhibitor Substances 0.000 description 1
- 101700048310 AMA2 Proteins 0.000 description 1
- 229940035678 ANTI-PARKINSON DRUGS Drugs 0.000 description 1
- 229940005513 ANTIDEPRESSANTS Drugs 0.000 description 1
- 229940116904 ANTIINFLAMMATORY THERAPEUTIC RADIOPHARMACEUTICALS Drugs 0.000 description 1
- 229940100197 ANTIMETABOLITES Drugs 0.000 description 1
- 229940005486 ANTIMIGRAINE PREPARATIONS Drugs 0.000 description 1
- 229940005529 ANTIPSYCHOTICS Drugs 0.000 description 1
- 241000238876 Acari Species 0.000 description 1
- 108010042708 Acetylmuramyl-Alanyl-Isoglutamine Proteins 0.000 description 1
- 231100000764 Actin inhibitor Toxicity 0.000 description 1
- 206010001897 Alzheimer's disease Diseases 0.000 description 1
- 206010002383 Angina pectoris Diseases 0.000 description 1
- 229940006211 Anticholinergic mydriatics and cycloplegics Drugs 0.000 description 1
- 229940065524 Anticholinergics inhalants for obstructive airway diseases Drugs 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 206010003246 Arthritis Diseases 0.000 description 1
- 208000006673 Asthma Diseases 0.000 description 1
- 206010003816 Autoimmune disease Diseases 0.000 description 1
- BDJRBEYXGGNYIS-UHFFFAOYSA-N Azelaic acid Chemical compound OC(=O)CCCCCCCC(O)=O BDJRBEYXGGNYIS-UHFFFAOYSA-N 0.000 description 1
- OIRCOABEOLEUMC-GEJPAHFPSA-N Bivalirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)CNC(=O)CNC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 OIRCOABEOLEUMC-GEJPAHFPSA-N 0.000 description 1
- 210000001218 Blood-Brain Barrier Anatomy 0.000 description 1
- 210000000988 Bone and Bones Anatomy 0.000 description 1
- 241000588807 Bordetella Species 0.000 description 1
- 229940052491 Bordetella pertussis Drugs 0.000 description 1
- 241000588832 Bordetella pertussis Species 0.000 description 1
- 210000000481 Breast Anatomy 0.000 description 1
- XWTYSIMOBUGWOL-UHFFFAOYSA-N Bricaril Chemical compound CC(C)(C)NCC(O)C1=CC(O)=CC(O)=C1 XWTYSIMOBUGWOL-UHFFFAOYSA-N 0.000 description 1
- 229960001113 Butorphanol Drugs 0.000 description 1
- IFKLAQQSCNILHL-QHAWAJNXSA-N Butorphanol Chemical compound N1([C@@H]2CC3=CC=C(C=C3[C@@]3([C@]2(CCCC3)O)CC1)O)CC1CCC1 IFKLAQQSCNILHL-QHAWAJNXSA-N 0.000 description 1
- 229940030609 CALCIUM CHANNEL BLOCKERS Drugs 0.000 description 1
- 229960004015 Calcitonin Drugs 0.000 description 1
- 102400000113 Calcitonin Human genes 0.000 description 1
- 108060001064 Calcitonin Proteins 0.000 description 1
- 102000004225 Cathepsin B Human genes 0.000 description 1
- 108090000712 Cathepsin B Proteins 0.000 description 1
- 241000606161 Chlamydia Species 0.000 description 1
- 206010008631 Cholera Diseases 0.000 description 1
- 241000193403 Clostridium Species 0.000 description 1
- 241000193449 Clostridium tetani Species 0.000 description 1
- 206010011401 Crohn's disease Diseases 0.000 description 1
- 108010041986 DNA Vaccines Proteins 0.000 description 1
- 206010061428 Decreased appetite Diseases 0.000 description 1
- 208000000264 Deglutition Disorders Diseases 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- 210000004207 Dermis Anatomy 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 206010012601 Diabetes mellitus Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- HESHRHUZIWVEAJ-JGRZULCMSA-N Dihydroergotamine Chemical compound C([C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@@](C(N21)=O)(C)NC(=O)[C@H]1CN([C@H]2[C@@H](C3=CC=CC4=NC=C([C]34)C2)C1)C)C1=CC=CC=C1 HESHRHUZIWVEAJ-JGRZULCMSA-N 0.000 description 1
- 229940052760 Dopamine agonists Drugs 0.000 description 1
- 206010013663 Drug dependence Diseases 0.000 description 1
- 206010013950 Dysphagia Diseases 0.000 description 1
- 102000018386 EGF Family of Proteins Human genes 0.000 description 1
- 108010066486 EGF Family of Proteins Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010014596 Encephalitis Japanese B Diseases 0.000 description 1
- 108010092674 Enkephalins Proteins 0.000 description 1
- 241000991587 Enterovirus C Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 210000003013 Erythroid Precursor Cells Anatomy 0.000 description 1
- 230000036826 Excretion Effects 0.000 description 1
- 210000002744 Extracellular Matrix Anatomy 0.000 description 1
- 229940028334 Follicle Stimulating Hormone Drugs 0.000 description 1
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 description 1
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 description 1
- 101710044881 GHRH Proteins 0.000 description 1
- UKVFVQPAANCXIL-FJVFSOETSA-N GLP-1 (1-37) amide Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 UKVFVQPAANCXIL-FJVFSOETSA-N 0.000 description 1
- 210000004907 Glands Anatomy 0.000 description 1
- 108060003199 Glucagon Proteins 0.000 description 1
- 229960004666 Glucagon Drugs 0.000 description 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N Glucagonum Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
- 108010015899 Glycopeptides Proteins 0.000 description 1
- 102000002068 Glycopeptides Human genes 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- MFWNKCLOYSRHCJ-BTTYYORXSA-N Granisetron Chemical compound C1=CC=C2C(C(=O)N[C@H]3C[C@H]4CCC[C@@H](C3)N4C)=NN(C)C2=C1 MFWNKCLOYSRHCJ-BTTYYORXSA-N 0.000 description 1
- 229960003727 Granisetron Drugs 0.000 description 1
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 1
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102000038586 Growth Hormone-Releasing Hormone Human genes 0.000 description 1
- 239000000095 Growth Hormone-Releasing Hormone Substances 0.000 description 1
- 206010061992 Haemophilia Diseases 0.000 description 1
- 208000009292 Hemophilia A Diseases 0.000 description 1
- 208000005252 Hepatitis A Diseases 0.000 description 1
- 208000002672 Hepatitis B Diseases 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- 208000009889 Herpes Simplex Diseases 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
- 241000701806 Human papillomavirus Species 0.000 description 1
- 229960003444 IMMUNOSUPPRESSANTS Drugs 0.000 description 1
- 238000004566 IR spectroscopy Methods 0.000 description 1
- DOUYETYNHWVLEO-UHFFFAOYSA-N Imiquimod Chemical compound C1=CC=CC2=C3N(CC(C)C)C=NC3=C(N)N=C21 DOUYETYNHWVLEO-UHFFFAOYSA-N 0.000 description 1
- 231100000608 Immunotoxin Toxicity 0.000 description 1
- 108010004484 Immunotoxins Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010021972 Inflammatory bowel disease Diseases 0.000 description 1
- 229940047124 Interferons Drugs 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 229940047122 Interleukins Drugs 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- PHTQWCKDNZKARW-UHFFFAOYSA-N Isoamyl alcohol Chemical compound CC(C)CCO PHTQWCKDNZKARW-UHFFFAOYSA-N 0.000 description 1
- QQVIHTHCMHWDBS-UHFFFAOYSA-N Isophthalic acid Chemical compound OC(=O)C1=CC=CC(C(O)=O)=C1 QQVIHTHCMHWDBS-UHFFFAOYSA-N 0.000 description 1
- LVHBHZANLOWSRM-UHFFFAOYSA-N Itaconic acid Chemical compound OC(=O)CC(=C)C(O)=O LVHBHZANLOWSRM-UHFFFAOYSA-N 0.000 description 1
- 201000005807 Japanese encephalitis Diseases 0.000 description 1
- 241000710842 Japanese encephalitis virus Species 0.000 description 1
- 210000003734 Kidney Anatomy 0.000 description 1
- 101710031012 LRRC59 Proteins 0.000 description 1
- 208000002473 Lacerations Diseases 0.000 description 1
- 108010028921 Lipopeptides Proteins 0.000 description 1
- 102000011965 Lipoprotein Receptors Human genes 0.000 description 1
- 108010061306 Lipoprotein Receptors Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 206010025169 Lyme disease Diseases 0.000 description 1
- 210000004698 Lymphocytes Anatomy 0.000 description 1
- 101710011942 MPN_625 Proteins 0.000 description 1
- 229940035363 MUSCLE RELAXANTS Drugs 0.000 description 1
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102000012750 Membrane Glycoproteins Human genes 0.000 description 1
- 108010090054 Membrane Glycoproteins Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 210000004379 Membranes Anatomy 0.000 description 1
- TTWJBBZEZQICBI-UHFFFAOYSA-N Metoclopramide Chemical compound CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC TTWJBBZEZQICBI-UHFFFAOYSA-N 0.000 description 1
- 229960003793 Midazolam Drugs 0.000 description 1
- DDLIGBOFAVUZHB-UHFFFAOYSA-N Midazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NC=C2CN=C1C1=CC=CC=C1F DDLIGBOFAVUZHB-UHFFFAOYSA-N 0.000 description 1
- 210000004400 Mucous Membrane Anatomy 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 229940083876 Muscle relaxants FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE Drugs 0.000 description 1
- 241000588653 Neisseria Species 0.000 description 1
- 241000588652 Neisseria gonorrhoeae Species 0.000 description 1
- 229940014995 Nitroglycerin Drugs 0.000 description 1
- 239000000006 Nitroglycerin Substances 0.000 description 1
- 108010061100 Nucleoproteins Proteins 0.000 description 1
- 102000011931 Nucleoproteins Human genes 0.000 description 1
- 229940074726 OPHTHALMOLOGIC ANTIINFLAMMATORY AGENTS Drugs 0.000 description 1
- 229960005343 Ondansetron Drugs 0.000 description 1
- FELGMEQIXOGIFQ-UHFFFAOYSA-N Ondansetron Chemical compound CC1=NC=CN1CC1C(=O)C(C=2C(=CC=CC=2)N2C)=C2CC1 FELGMEQIXOGIFQ-UHFFFAOYSA-N 0.000 description 1
- 108010093625 Opioid Peptides Proteins 0.000 description 1
- 102000001490 Opioid Peptides Human genes 0.000 description 1
- 229940005542 PARASYMPATHOMIMETICS Drugs 0.000 description 1
- 108091005990 PEGylated Proteins Proteins 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 240000002390 Pandanus odoratissimus Species 0.000 description 1
- 235000005311 Pandanus odoratissimus Nutrition 0.000 description 1
- 208000003154 Papilloma Diseases 0.000 description 1
- 208000006551 Parasitic Disease Diseases 0.000 description 1
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N Pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 1
- 229960001412 Pentobarbital Drugs 0.000 description 1
- 108091005771 Peptidases Proteins 0.000 description 1
- 102000035443 Peptidases Human genes 0.000 description 1
- 108010001014 Plasminogen Activators Proteins 0.000 description 1
- 102000001938 Plasminogen Activators Human genes 0.000 description 1
- 208000000474 Poliomyelitis Diseases 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 108010033725 Recombinant Proteins Proteins 0.000 description 1
- 102000007312 Recombinant Proteins Human genes 0.000 description 1
- 241000725643 Respiratory syncytial virus Species 0.000 description 1
- 206010039073 Rheumatoid arthritis Diseases 0.000 description 1
- 241000282849 Ruminantia Species 0.000 description 1
- 229940076279 Serotonin Drugs 0.000 description 1
- 241000607768 Shigella Species 0.000 description 1
- 206010040550 Shigella infection Diseases 0.000 description 1
- BNRNXUUZRGQAQC-UHFFFAOYSA-N Sildenafil Chemical compound CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 BNRNXUUZRGQAQC-UHFFFAOYSA-N 0.000 description 1
- 241000580858 Simian-Human immunodeficiency virus Species 0.000 description 1
- 102000005632 Single-Chain Antibodies Human genes 0.000 description 1
- 108010070144 Single-Chain Antibodies Proteins 0.000 description 1
- 102000013275 Somatomedins Human genes 0.000 description 1
- 108010026080 Somatomedins Proteins 0.000 description 1
- 241000193998 Streptococcus pneumoniae Species 0.000 description 1
- 229940031000 Streptococcus pneumoniae Drugs 0.000 description 1
- 229960000195 Terbutaline Drugs 0.000 description 1
- KKEYFWRCBNTPAC-UHFFFAOYSA-N Terephthalic acid Chemical compound OC(=O)C1=CC=C(C(O)=O)C=C1 KKEYFWRCBNTPAC-UHFFFAOYSA-N 0.000 description 1
- 206010043376 Tetanus Diseases 0.000 description 1
- 229960002372 Tetracaine Drugs 0.000 description 1
- GKCBAIGFKIBETG-UHFFFAOYSA-N Tetracaine Chemical compound CCCCNC1=CC=C(C(=O)OCCN(C)C)C=C1 GKCBAIGFKIBETG-UHFFFAOYSA-N 0.000 description 1
- 241000242541 Trematoda Species 0.000 description 1
- 206010046980 Varicella Diseases 0.000 description 1
- 206010047163 Vasospasm Diseases 0.000 description 1
- 241000607626 Vibrio cholerae Species 0.000 description 1
- 210000002268 Wool Anatomy 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Xylocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- 208000003152 Yellow Fever Diseases 0.000 description 1
- 230000035507 absorption Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000000996 additive Effects 0.000 description 1
- 239000001361 adipic acid Substances 0.000 description 1
- 235000011037 adipic acid Nutrition 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 238000007605 air drying Methods 0.000 description 1
- 229940024142 alpha 1-Antitrypsin Drugs 0.000 description 1
- 108010050122 alpha 1-Antitrypsin Proteins 0.000 description 1
- 102000015395 alpha 1-Antitrypsin Human genes 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 239000002269 analeptic agent Substances 0.000 description 1
- 239000004037 angiogenesis inhibitor Substances 0.000 description 1
- 230000000578 anorexic Effects 0.000 description 1
- 230000003266 anti-allergic Effects 0.000 description 1
- 230000002456 anti-arthritic Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000001078 anti-cholinergic Effects 0.000 description 1
- 230000002429 anti-coagulation Effects 0.000 description 1
- 230000001773 anti-convulsant Effects 0.000 description 1
- 230000001430 anti-depressive Effects 0.000 description 1
- 230000003474 anti-emetic Effects 0.000 description 1
- 230000000118 anti-eoplastic Effects 0.000 description 1
- 230000000843 anti-fungal Effects 0.000 description 1
- 230000001387 anti-histamine Effects 0.000 description 1
- 230000002924 anti-infective Effects 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 230000001062 anti-nausea Effects 0.000 description 1
- 230000003579 anti-obesity Effects 0.000 description 1
- 230000003262 anti-osteoporosis Effects 0.000 description 1
- 230000000111 anti-oxidant Effects 0.000 description 1
- 230000001028 anti-proliferant Effects 0.000 description 1
- 230000001139 anti-pruritic Effects 0.000 description 1
- 230000000561 anti-psychotic Effects 0.000 description 1
- 230000001754 anti-pyretic Effects 0.000 description 1
- 230000000840 anti-viral Effects 0.000 description 1
- 239000000924 antiasthmatic agent Substances 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 239000002111 antiemetic agent Substances 0.000 description 1
- 229940121375 antifungals Drugs 0.000 description 1
- 229940006131 antiglaucoma preparations and miotics Parasympathomimetics Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000003080 antimitotic agent Substances 0.000 description 1
- 229960000070 antineoplastic Monoclonal antibodies Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000000939 antiparkinson agent Substances 0.000 description 1
- 239000003908 antipruritic agent Substances 0.000 description 1
- 239000000164 antipsychotic agent Substances 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 229940121357 antivirals Drugs 0.000 description 1
- 201000001320 atherosclerosis Diseases 0.000 description 1
- 229960001500 bivalirudin Drugs 0.000 description 1
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 1
- 239000000480 calcium channel blocker Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 101710025091 cbbGC Proteins 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000002490 cerebral Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 201000006082 chickenpox Diseases 0.000 description 1
- 108091006028 chimera Proteins 0.000 description 1
- 238000007374 clinical diagnostic method Methods 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 201000009230 common cold Diseases 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 238000000942 confocal micrograph Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000001808 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 210000004748 cultured cells Anatomy 0.000 description 1
- 238000007872 degassing Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 239000000412 dendrimer Substances 0.000 description 1
- 229920000736 dendritic polymer Polymers 0.000 description 1
- 230000001419 dependent Effects 0.000 description 1
- 239000007933 dermal patch Substances 0.000 description 1
- 239000003241 dermatological agent Substances 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 229960002086 dextran Drugs 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 150000004985 diamines Chemical class 0.000 description 1
- 201000008286 diarrhea Diseases 0.000 description 1
- 150000001991 dicarboxylic acids Chemical class 0.000 description 1
- 229960004704 dihydroergotamine Drugs 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 239000003136 dopamine receptor stimulating agent Substances 0.000 description 1
- 230000005670 electromagnetic radiation Effects 0.000 description 1
- 210000002257 embryonic structures Anatomy 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 238000005530 etching Methods 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000001605 fetal Effects 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037240 fusion proteins Human genes 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 229960003711 glyceryl trinitrate Drugs 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 201000010284 hepatitis E Diseases 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 229920001477 hydrophilic polymer Polymers 0.000 description 1
- 229920001600 hydrophobic polymer Polymers 0.000 description 1
- 230000000147 hypnotic Effects 0.000 description 1
- 239000003326 hypnotic agent Substances 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 229960002751 imiquimod Drugs 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000001861 immunosuppresant Effects 0.000 description 1
- 239000002596 immunotoxin Substances 0.000 description 1
- 230000002637 immunotoxin Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000002329 infrared spectrum Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- KFZMGEQAYNKOFK-UHFFFAOYSA-N iso-propanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 150000002605 large molecules Chemical class 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000003754 machining Methods 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 210000004962 mammalian cells Anatomy 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 201000009906 meningitis Diseases 0.000 description 1
- 229960004503 metoclopramide Drugs 0.000 description 1
- 238000005459 micromachining Methods 0.000 description 1
- 229960000060 monoclonal antibodies Drugs 0.000 description 1
- 102000005614 monoclonal antibodies Human genes 0.000 description 1
- 108010045030 monoclonal antibodies Proteins 0.000 description 1
- 201000003152 motion sickness Diseases 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- BSOQXXWZTUDTEL-ZUYCGGNHSA-N muramyl dipeptide Chemical compound OC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)O[C@@H](O)[C@@H]1NC(C)=O BSOQXXWZTUDTEL-ZUYCGGNHSA-N 0.000 description 1
- 239000003158 myorelaxant agent Substances 0.000 description 1
- 230000003533 narcotic Effects 0.000 description 1
- 201000009240 nasopharyngitis Diseases 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drugs Drugs 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- TWHMVKPVFOOAMY-UHFFFAOYSA-N octanedioic acid Chemical compound OC(=O)CCCCCCC(O)=O.OC(=O)CCCCCCC(O)=O TWHMVKPVFOOAMY-UHFFFAOYSA-N 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Polymers 0.000 description 1
- 229940005943 ophthalmologic Antivirals Drugs 0.000 description 1
- 239000003399 opiate peptide Substances 0.000 description 1
- 238000000399 optical microscopy Methods 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 210000000056 organs Anatomy 0.000 description 1
- 230000001499 parasympathomimetic Effects 0.000 description 1
- 239000000734 parasympathomimetic agent Substances 0.000 description 1
- 230000002093 peripheral Effects 0.000 description 1
- 238000002428 photodynamic therapy Methods 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000033885 plasminogen activation Effects 0.000 description 1
- 239000000106 platelet aggregation inhibitor Substances 0.000 description 1
- 229920000867 polyelectrolyte Polymers 0.000 description 1
- 239000002861 polymer material Substances 0.000 description 1
- 230000003334 potential Effects 0.000 description 1
- OZAIFHULBGXAKX-UHFFFAOYSA-N precursor Substances N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 1
- 230000003449 preventive Effects 0.000 description 1
- 230000000750 progressive Effects 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 230000004224 protection Effects 0.000 description 1
- 239000003223 protective agent Substances 0.000 description 1
- 239000003368 psychostimulant agent Substances 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 108091006066 receptor inhibitors Proteins 0.000 description 1
- 239000003488 releasing hormone Substances 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 230000000717 retained Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000004621 scanning probe microscopy Methods 0.000 description 1
- 230000001624 sedative Effects 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 230000001568 sexual Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 229960003310 sildenafil Drugs 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 230000037335 skin penetration Effects 0.000 description 1
- 230000005586 smoking cessation Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000002294 steroidal antiinflammatory agent Substances 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000002731 stomach secretion inhibitor Substances 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000003868 thrombin inhibitor Substances 0.000 description 1
- 230000002537 thrombolytic Effects 0.000 description 1
- 229960000103 thrombolytic agents Drugs 0.000 description 1
- 102000002689 toll-like receptors Human genes 0.000 description 1
- 108020000411 toll-like receptors Proteins 0.000 description 1
- 229940026754 topical Antivirals Drugs 0.000 description 1
- 230000002936 tranquilizing Effects 0.000 description 1
- 239000003204 tranquilizing agent Substances 0.000 description 1
- 230000037317 transdermal delivery Effects 0.000 description 1
- 201000008297 typhoid fever Diseases 0.000 description 1
- 230000003612 virological Effects 0.000 description 1
- 239000011345 viscous material Substances 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Abstract
A device is provided which is suitable for delivering at least one nanoparticle(s) to a subject. The device can be used to deliver a variety of nanoparticles, for example, therapeutic agents, directly through the outer layers of the skin without passing completely through the epidermis of the subject. Thus the device can be used to deliver therapeutic agents to a predetermined depth and avoid disturbing the pain receptors in the skin. Thus the device can be used to deliver agents, including therapeutic agents, in a non-invasive manner. A method of fabricating devices with associated nanoparticles is also provided.
Description
MICRO-ARRANGEMENT DEVICE
FIELD OF THE INVENTION The present invention relates to a method and device for the delivery of nanoparticles. In particular, the present invention relates to microneedles and microneedle arrays suitable for the delivery of nanoparticles.
BACKGROUND OF THE INVENTION There has been increased interest in methods for the effective delivery of agents to organisms, including the delivery of therapeutic agents such as drugs. The delivery of agents to organisms is complicated by the inability of many molecules to penetrate biological barriers. Biological barriers for which it is preferable to deliver molecules through even the skin (or parts of it); the matoencephalic barrier h; mucous tissue
(eg, oral, nasal, ocular, vaginal, urethral, gastrointestinal, respiratory); blood vessels; lymphatic vessels; or cell membranes (e.g., for the introduction of material into a cell or cells). Traditional methods of delivery such as oral administration are not suitable for all types of drugs because many drugs are destroyed in the digestive tract or immediately absorbed by the liver. Intravenous administration via hypodermic needles is also considered highly invasive and results in potential undesirable peak concentrations of the delivered drug. In addition, traditional delivery methods are often not useful for effective targeting of the delivered drug. One approach to the delivery of drugs through the skin is through the use of transdermal patches. A transdermal patch can provide significantly more effective blood levels of a beneficial drug because the drug is not delivered at peak concentrations as is the case with hypodermic injection and most oral administrations. In addition, drugs that are administered via transdermal patches are not subject to the severe environment of the digestive tract. Currently, transdermal patches are available for a specific number of drugs. Commercially available examples of transdermal patches include scopolamine for the prevention of motion sickness, nicotine as an aid to smoking cessation, nitroglycerin for the treatment of coronary angina pain, and estrogen for hormone replacement. Generally, these systems have drug pools sandwiched between an impermeable support and a type of membrane that constantly control the rate of delivery of the drug. Such patches depend on the ability of the drug to diffuse through the outermost layer of the skin, the stratum corneum, and eventually within the circulatory system of the patient. The stratum corneum is a complex structure of keratinized compact cell remnants that has an approximate thickness of 10-30 μm and forms an effective barrier to prevent the passage in and out of most substances. The degree of diffusion through the stratum corneum depends on the porosity of the skin, the size and polarity of the drug molecules, and the concentration gradient across the stratum corneum. These factors generally limit this mode of delivery to a very small number of useful drugs with very small molecules or unique electrical characteristics. A common method to increase the porosity of the skin is the formation of micropores or cuts through the stratum corneum. Many drugs can be administered effectively by penetrating the stratum corneum and delivering the drug to the skin at or below the stratum corneum. Devices for penetrating the stratum corneum generally include a plurality of microtable needles or sheets having a length to penetrate the stratum corneum without passing completely through the epidermis.
Examples of these devices are described in Pat. E.U. No. 5,879,326 to Godshall et al. , Pat. E.U. No. 5,250,023 to Lee et al and Pat. E.U. No. 6,334,856. Nevertheless, the efficacy of these methods to improve transdermal delivery has been limited, because after the micropores have been formed, it is necessary to administer the drug separately in the treated skin. In addition, these devices are usually manufactured with silicon or other metals using etching methods. For example, Pat. E.U. No. 6,312,612 to Sherman et al. describes a method for forming a microneedle array using Microelectromechanical Systems (MEMS) technology and standard microfabrication techniques. Although partially effective, the resulting microneedle devices are relatively expensive to manufacture and difficult to produce in large quantities. In addition, these arrangements have limited application in the delivery of a very limited variety of molecules.
SUMMARY OF THE INVENTION According to one aspect, the present invention provides a device suitable for delivering at least one nanoparticle comprising a microneedle having at least one nanoparticle that is associated with at least part of a surface of the microneedle and / or at least part of the tissue of the microneedle. The size of nanoparticle (s) may be in the range of about 1 to about 1000 nm. Preferably, the size of the nanoparticle may be between about 50 to about 500 nm. Preferably the device has at least two microneedles. The microneedles can be arranged in an order without pattern or other similar configuration. In other instrumentations, the microneedles can be arranged in at least one array. Preferably the nanoparticle (s) can be associated with at least part of the outer surface of the microneedle. Preferably the nanoparticle (s) can be associated with pores on the surface of the microneedles. In some instrumentations, the nanoparticle (s) may be associated with at least a portion of the tissue of the microneedle. The pore (s), cavities or the like can be of two or more shapes, cross sections that are selected from the group comprising circular, elongate, square, triangular, etc. In other instrumentations, the nanoparticle (s) can be associated with internal pores in the tissue of the microneedle. Preferably the association may comprise a covalent bond or non-covalent interactions. The non-covalent interactions can be selected from one or more of the group comprising ionic bonds, hydrophobic interactions, hydrogen bonds, Van der Waals forces or dipole-dipole bonds. Preferably the association is via a covalent link to a functional group in the microneedle. Preferably the functional group (s) can be selected from the group comprising COOR, CONR2, NH2, SH, and OH, where R comprises an H; organic or inorganic chain. The microneedle (s) can be manufactured from a porous or non-porous material that is selected from the group comprising metals, natural or synthetic polymers, glasses, ceramics, or combinations of two or more thereof. With this instrumentation, the polymer can be selected from the group comprising: polyglycolic acid / polylactic acid, polycaprolactone, polyhydroxybutyrate-valerate, polyorthoester, and polyethylene oxide / polybutylene terephthalate, polyurethane, silicone polymers, and polyethylene terephthalate, polyamine plus a sulphate tri-layer of dextran, high molecular weight poly-L-lactic acid, fibrin, methyl methacrylate (MMA) (hydrophobic, 70 mol%) and 2-hydroxyethyl methacrylate (HEMA) (hydrophilic 30 mol%), poly elastomeric polymers amide) (co-PEA), polyetheretherketone (Peek-Optima), biocompatible thermoplastic polymer, conductive polymers, polystyrene or combinations of two or more thereof. The microneedles may include a layer or coating on at least a portion of the surface of the microneedle (s) of an electrically conductive material. Preferably the electrically conductive material can be selected from the group comprising conductive polymers; Compound conductive materials; doped polymers, conductive metallic materials or combinations of two or more thereof. The conductive polymer can be selected from the group comprising substitutable or irreplaceable polymers comprising polyaniline; polypyrrole; polysilicones; poly (3, 4-ethylenedioxythiophene); polymer doped with carbon nanotubes; polymer doped with metal nanoparticles, or combinations of two or more thereof. Preferably the thickness of the layer or coating can be from about 20 nm to about 20 μm. The electrically conductive material can be layered or coated on the microneedle (s) by electrodeposition. At least one nanoparticle can be contained in the electrically conductive material. Preferably the nanoparticle (s) can be delivered to an organism and the microneedle (s) can be manufactured from a biocompatible material, the microneedle (s) can (even) be non-biodegradable (s). The microneedle can be solid. The microneedle may have nanosize pores or cavities on its surface. The nanoparticle (s) can (are) an active agent (s). In other instrumentation, the nanoparticle (s) can be a carrier for an agent. Preferably the nanoparticle may be associated with an active agent. The active agent (s) can be associated with the nanoparticle (s) by a covalent bond or non-covalent interactions. The non-covalent interactions can be selected from any or any of the group comprising ionic bonds, hydrophobic interactions, hydrogen bonds, Van der aals forces or dipole-dipole bonds. The nanoparticle can encapsulate the active agent. In another instrumentation, the active agent can be incorporated into the nanoparticle (s). Preferably the nanoparticle (s) can be made from a material that is selected from the group comprising metals, semiconductors, inorganic or organic polymers, magnetic colloidal materials, or combinations of two or more thereof. The metal can be selected from the group comprising gold, silver, nickel, copper, titanium, platinum, palladium and its oxides or combinations of two or more thereof. The polymer can be selected from the group comprising a conductive polymer; a hydrogel; agarose; polyglycolic acid / polylactic acid; polycaprolactone; polyhydroxybutyrate-valerate; poliortoester; polyethylene oxide / polybutylene terephthalate; polyurethane; polymeric silicon compounds; polyethylene terephthalate; polyamine plus a trilayer of dextran sulfate; high molecular weight poly-L-lactic acid; fibrin; copolymers of methyl methacrylate (MMA) and 2-hydroxyethyl methacrylate (HEMA), poly (ester-amide) elastomeric polymers (co-PEA); n-butyl cyanoacrylate; polyetheretherketone (Peek-Optima); polystyrene or combinations of two or more thereof. Preferably the active agent can be a biological agent. With this instrumentation, the biological agent can be a therapeutic and / or diagnostic agent. Preferably the therapeutic agent can be selected from the group comprising all microorganisms, viruses, viruses such as particles, peptides, proteins, carbohydrates, nucleic acid molecules, an oligonucleotide fragment (s) or DNA or RNA, lipids, organic molecules, molecules biologically active inorganics or combinations of two or more thereof. Preferably the therapeutic agent can be a vaccine. The vaccine can be selected from the group comprising a vector containing a nucleic acid, oligonucleotide, expression gene as a vaccine or combinations of two or more thereof. Preferably the vaccine can be selected from proteins or peptides as vaccines for diseases that are selected from the group comprising Johnes disease, hepatic dysphagia, bovine mastitis, meningococcal disease.
The vaccine may comprise Johnes peptide disease. With this instrumentation, the peptide can be selected from the group comprising: NVESQPGGQPNT (SEQ ID No 1); QYTDHHSSLLGP (SEC ID No 2); LYRPSDSSLAGP (SEC ID No 3); and / or its variants. The vaccine may comprise peptides from bovine mastitis disease. With this implementation, the peptide may be selected from the group comprising: MKKWFLILMLLGIFGCATQPSKVAAITGYDSDYYARYIDPDENKITFAINVDGF VEGSNQEILIRGIHHVLTDQNQKIVTKAELLDAIRHQMVLLQLDYSYELVDFAP DAQLLTQDRRLLFANQNFEESVSLEDTIQEYLLKGHVILRKRVEEPITHPTETAN IEYKVQFATKDGEFHPLPIFVDYGEKHIGEKLTSDEFRKIAEEKLLQLYPDYMID QKEYTIIKHNSLGQLPRYYSYQDHFSYEIQDRQRIMAKDPKSGKELGETQSIDN VFEKYLITKKSYKP (SEQ ID No 4); ILIRGIHHVL (SEC ID No 5); IRHQMVLLQL (SEC ID No 6); and / or its variants. The vaccine may comprise a peptide of Meningococcal disease. With this instrumentation, the peptide can be selected from the group comprising: GRGPYVQADLAYAYEHITHDYP (SEQ ID NO 7) STVSDYFRNIRTHSIHPRVSVGYDFGGWRIAADYARYRK NDNKYSV (SEQ ID NO 8);
and / or its variants. The vaccine may include a Hepa ti tiis Virus
C. With this instrumentation, the peptide can be selected from the group comprising: QDVKFPGGGVYLLPRRGPRL (SEQ ID No. 9); RRGPRLGVRATRKTSERSQPRGRRQ (SEC ID No 10); PGYPWPLYGNEGCGWAG LLSPRGS (SEC ID No 11); and / or its variants. The diagnostic agent can be a detectable agent. Preferably the detectable agent is used in an analysis. The outer diameter of the microneedle (s) may be between about 1 μm and about 100 μm. The length of the microneedle (s) can be between about 20 μm and 1 mm. Preferably the length of the microneedle (s) can be between about 20 μm and 250 μm. Preferably the microneedle (s) can be adapted to provide an insertion depth of at least about 100 to 150 μm. Preferably the shape of the tip of the microneedle (s) can be selected from the group comprising the square, circular, oval, cross needle, triangular, chevron, serrated chevron, half moon or diamond shapes. In an instrumentation, the complete microneedle can be manufactured from nanoparticles. According to another aspect, the present invention provides a method for manufacturing a device for the delivery of nanoparticles, the device comprises an array of microneedles and at least one nanoparticle that is associated with at least part of a surface of the microneedle, the method comprising the steps of: (i) covering at least a portion of the surface of a microneedle array that is molded with the nanoparticles; (ii) molding the microneedles; where after leaving the mold, the nanoparticles are associated with the surface of the microneedles. In still another aspect, the present invention provides a method for manufacturing a device for delivery of nanoparticles, the device comprising an array of microneedles and at least one nanoparticle that associates with the pores on the surface of the microneedle, the method comprising the steps of: i) inducing porosity on at least a portion of the surface of the microneedles; ii) associate the nanoparticles with at least a part of the pores. Preferably the step of inducing a porosity on the surface of the microneedles comprises the steps of: i) selectively leaching micro or nanoparticles that are incorporated into the surface of the microneedle; ii) give physical, chemical or electrochemical treatment to the surface of the microneedles. In a further aspect, the present invention provides a method for manufacturing a device for the delivery of nanoparticles, the device comprising an array of microneedles and at least one nanoparticle that is associated with at least part of the tissue of the microneedle, the method comprising the steps of: molding the microneedles in the presence of the nanoparticles; wherein after leaving the mold, the nanoparticles are associated with at least part of the tissue of the microneedles. In another additional aspect, the present invention provides a method for manufacturing a device for the delivery of nanoparticles, the device comprising an array of microneedles and at least one nanoparticle that is associated with at least a portion of the outer surface of the microneedle, the method comprising the steps of: (i) functionalizing at least a portion of the outer surface of the microneedles with functional groups; (ii) linking the nanoparticles to the introduced functional groups. Preferably the step of functionalizing can be selected from the group comprising oxidation, reduction, substitution, crosslinking, plasma, heat treatment or combinations of two or more thereof. Preferably the functional group (s) introduced (s) can be selected from the group comprising COOR, CONR2, NH2, SH, and OH, where R comprises a
H or an organic or inorganic chain. The methods of the present invention may include the step of coating at least a portion of the microneedles with an electrically conductive material. Preferably the electrically conductive material can be selected from the group comprising the conductive polymer; composite conductive material; doped polymer, metallic conductive materials or compounds thereof. Preferably the conductive polymer can be selected from the group of substitutable or irreplaceable polymers comprising polyaniline; polypyrrole; polysilicone; poly (3, -ethylenedioxythiophene); polymer doped with metal nanoparticles; or polymer doped with carbon nanotubes.
In a further aspect, the present invention provides a device suitable for delivering at least one agent comprising a microneedle that is made of an electrically conductive polymer and / or electrically conductive polymer composite, the microneedle having at least one agent which is associated with at least part of a surface of the microneedle and / or at least part of the tissue of the microneedle. In a further aspect, the present invention provides a device suitable for delivering at least one agent comprising a microneedle that is made of an electrically conductive material, the microneedle having at least one agent that is associated with at least part of a surface of the microneedle and / or at least part of the tissue of the microneedle. The present invention also provides methods for using the microneedles to deliver nanoparticles. Thus according to another aspect, the present invention provides a method for delivering at least one nanoparticle (s) to a patient, wherein the delivery includes the steps of contacting at least one area of the patient with at least one microneedle associated with at least one nanoparticle, wherein at least one nanoparticle is delivered to the patient.
BRIEF DESCRIPTION OF THE FIGURES Figure 1 shows a schematic view of the cross sections of the needle. Figure 2 shows a top view of PDMS microneedles with dye molecules that are added to dye the patches and microneedle. Figure 3 shows a side view of the crosses shown in Figure 2. Figure 4 shows a side view of a microneedle array, the needles have a diameter of 20μm at the base and a degree of inclination of 50μm. Figure 5 shows a top view of a sheet of multiple microneedle array patches. Figure 6 shows an enlarged side view of a section of the array patch shown in Figure 5. Figure 7 shows a schematic flow diagram of a process for forming nanopore (s) on the surface of a microneedle. Figure 8 shows a fluorescent image of an array of circular microneedles showing the coverage of the quantum dot coating. Figure 9 shows a fluorescent image of a cross-shaped array of microneedles showing the coverage of the quantum dot coating. Figure 10 shows a scanning electron micrograph (SEM) image of insulin nanoparticles in PLGA microneedles. Figure 11 shows an SEM image of a microneedle array that is coated with insulin nanoparticles. Figure 12 shows a fluorescent confocal microscopy image of a skin patch that is removed from a hairless mouse. Figure 13 shows a fluorescent image of confocal microscopy at a total depth of approximately 60 μm.
DETAILED DESCRIPTION OF THE INVENTION The devices described herein are useful for transporting agents to or through biological barriers that include the skin (or parts thereof); the blood-brain barrier; mucosal tissue (eg, oral, nasal, ocular, vaginal, urethral, gastrointestinal, respiratory); blood vessels; lymphatic vessels; or cell membranes (e.g., for the introduction of material into a cell or cells). Biological barriers can be found in humans or other types of animals, as well as in plants, insects, or other organisms, which include bacteria, yeast, fungi, and embryos. The microneedle devices can be used in internal tissues with the help of a catheter or laparoscope. For certain uses, such as for delivery of drug to an internal tissue, the device can be surgically implanted. The present invention provides agents that can be a protein, peptide, homogenized cell, whole organism or glycoprotein effective as a detecting agent or protective agent. The present invention also provides a presentation configuration of the agent that can be used to detect, individual molecules, multimer, aggregates, or multimer through the nanoparticle anchor; in consideration of that, to deliver
(vaccination) The configuration of the biological molecule can also comprise: individual molecules, multimer, aggregates, or multimer through the nanoparticle anchor. The nanoparticle anchor can be through nanoparticles of gold, silver, titanium, agarose, proteins, dendrimers, proteins or polymers. The preferred option is the presentation of multimeric nanoparticle.
The present invention also has applications in the food industry for quality detection and for one or more infectious agent (s), the infectious agent can be a microorganism. The microorganism can be selected from one or more of the group comprising viruses, bacteria, protozoa and / or fungi. The inventors of the present invention have unexpectedly discovered a novel delivery structure and composition, as well as the composition and configuration of the biological reagent to be delivered and methods for its production. By forming the agents to deliver in the presence of removable and / or degradable nanoparticles of different composition to the composition of the delivery molecules, the nanostructured molecules incorporate a nanoporous structure capable of retaining large and small molecules and nanoparticles - biological molecules that are anchored to be delivered as vaccines and therapeutic. It will also be recognized that a novel polymer system number that when subjected to a certain tension changes its composition to have a nanoparticular structure that is different from the surrounding polymer, and said polymers can have an application with its improved solubility (degradation properties). for the delivery of reagents from polymer array patches. The mentioned polyvalent nanoparticular vaccination particles can be released from polymer patches with the penetration of the interstitial layer into living tissue. The polyvalent nanoparticular detector agents mentioned can be retained on the surface of the polymer patches with conductive properties for signal transduction. The authors of the present invention have surprisingly found that the identical polymer is used to present (delivery / anchor detector) the nanostructured molecule (s), and also unexpectedly, a polymer which, although is biocompatible, preferably it is not biodegradable and therefore has advantages of molecule delivery speed without requiring long-term dependent degradation. In the aspect of the present invention that has application for the delivery of vaccination through the stratum corneum, the residence time in this layer is of an estimated time of two weeks. In a further aspect of the present invention a process is provided for delivering molecule (s) precisely to the proper depth using the microneedle arrays that have nanostructured delivery molecules. The construction of the device and control of the polymer structure is carried out by means of the inclusion of materials with nanoparticle size with properties to allow the dissolution of the nanoparticles to create a mesoporous structure with nanoporous cavities to retain reagents or structured nanoparticle reagents , which are delivered by means of the structure of the fix patch. Both hollow and solid penetration arrays (solid needle) are constructed with any of a variety of sizes between 20 μm and 250 μm but the preferred sizes (lengths) are 25 μ and 150 μm. The dimensions of the complete arrangement could normally be 1 square cm or with a diameter of 1 cm. However, the size of the patch patch can be based on the amount of material being delivered and the needle density that is packed in the patches. It is preferable that the microneedles be in an array format, but they can be arranged randomly. The disposition of the microneedles can be a result of the method used in manufacturing. The microneedles can be arranged in such a way that more than one reagent can be coated and delivered from the array itself. A polymer that when subject to certain stresses changes its composition to have a nanoparticle structure that is different from the surrounding polymer, and said polymers can have an application with their improved solubility (degradation properties) for the delivery of reagents from polymer array patches. A polymer that contains a nanoparticle that can be selectively removed to produce nano-size pores or cavities on the surface of the microneedle. The microneedle array patches of the present invention also provide applications for the treatment and prevention of human diseases. Preventive vaccination of a wide variety of human disease states can be achieved, for example, the present microneedle arrays can be used to vaccinate against any or all of the disease states that are selected from the group comprising infectious diseases (which include but they are not limited to meningococcal disease and tuberculosis) and autoimmune diseases (which include but are not limited to multiple sclerosis and rheumatoid arthritis). As used in the present invention, the term "nanoparticle" is intended to include particles comprising sizes from about 1 nm to about 1000 nm. Preferably, the nanoparticles are in the range of about 50 nm to about 500 nm. As used in the present invention, the term "tissue" is intended to describe the material of which the particle is composed. As used in the present invention, the term "biocompatible" is intended to describe molecules that are not toxic to cells. The compounds are "biocompatible" if their addition to in vitro cells results in less than or equal to 20% cell death and does not induce inflammation or other similar adverse effects in vivo. As used in the present invention, "associating" or "associated" includes physical, chemical, and physiochemical adhesion. As used in the present invention, "biodegradable" includes those compounds that, when introduced into cells, are broken down by the cellular machinery into components that the cells can either reuse or dispose of without any significant toxic effect on the cells (that is, just under 20% of the cells die). The agent that can be delivered using the present invention includes any therapeutic substance that possesses suitable therapeutic characteristics. These agents may be selected from any or any of the group comprising: thrombin inhibitors, antithrombogenic agents, thrombolytic agents, fibrinolytic agents, vasospasm inhibitors, calcium channel blockers, vasodilators, antihypertensive agents, antimicrobial agents, antibiotics, receptor inhibitors, surface glycoprotein, antiplatelet agents, antimitotic agents, icrotubular inhibitors, antisecretory agents, actin inhibitors, remodeling inhibitors, antisense nucleotides, antimetabolites, antiproliferatives, anti-cancer chemotherapeutic agents, steroidal anti-inflammatory agents or nonsteroidal anti-inflammatory drugs, immunosuppressive agents, growth hormone antagonists , growth factors, dopamine agonists, therapeutic radioagents, peptides, proteins, enzymes, components of the extracellular matrix, ACE inhibitors, free radical collectors, chelating agents, antioxidants, antipolymerases, antiviral agents, photodynamic therapy agents, and gene therapy agents. In particular, the therapeutic substance can be selected from any or any of the group comprising alpha 1 antitrypsin, antiangiogenesis agents, antisense, butorphanol, calcitonin and the like, ceredase, COX-II inhibitors, dermatological agents, dihydroergotamine, agonists and antagonists of dopamine, enkephalins and other opioid peptides, epidermal growth factors, erythropoietin and the like, follicle-stimulating hormone, G-CSF, glucagon, GM-CSF, granisetron, growth hormone and the like (which includes growth hormone releasing hormone), growth hormone antasts, hirudin and the like of hirudin such as hirulog, IgE suppressors, imiquimod, insulin, insulinotropin and the like, insulin-like growth factors, interferons, interleukins, luteinizing hormone, luteinizing hormone releasing hormones and the like, heparins, low molecular weight heparins and other natural, modified, or synthetic glycoaminoglycans, M-CSF, metoclopramide, midazolam, monoclonal antibodies, pegylated antibodies, pegylated proteins or any proteins that are modified with hydrophilic or hydrophobic polymers or functional groups additional, fusion proteins, fragments of single chain antibodies or the same with any combination of adhered proteins, macromolecules, or additional functional groups thereof, narcotic analgesics, nicotine, non-steroidal anti-inflammatory agents, oligosaccharides, ondansetron, parathyroid hormone and the like , ant parathyroid hormone asts, prostaglandin antasts, prostaglandins, recombinant soluble receptors, scopolamine, serotonin asts and antasts, sildenafil, terbutaline, thrombolytics, tissue plasminogen activators, TNF-, and TNF- antasts, vaccines, with or without carriers / adjuvants, including prophylactic and therapeutic antigens (including but not limited to subunit protein, peptide and polysaccharide, polysaccharide conjugate, toxoids, gene-based vaccines, live attenuated, reassortant, inactive, whole cells, viral vectors and bacterial) in connection with, addiction, arthritis, cholera, cocaine addiction, diphtheria, tetanus, HIB, Lyme disease, meningococcus, measles, mumps, rubella, chicken pox, yellow fever, respiratory syncytial virus, Japanese encephalitis transmitted by ticks , pneumococcus, streptococcus, typhoid, influenza, hepatitis, which includes hepatitis A, B, C and E, oti ti s media, rabies, polio, HFV, parainfluenza, rotavirus, Epstein Barr virus, CMV, chlamydia, hemophilia without classification, moraxela catarrhalis, human papilloma virus, tuberculosis that includes BCG, rrhea, asthma, atherosclerosis of malaria, E-coli, Alzheimer's disease, H. pylori, salmonella, diabetes, cancer, herpes simplex, human papilloma and other similar substances that include all of major therapeutics such as agents for the common cold, antiadictions, anti-allergies, antiemetics, anti-obesity, antiosteoporotic, anti-infective, analgesics, anesthetics, anorexics, antiarthritics, anti-asthmatic agents, anticonvulsants, antidepressants, antidiabetic agents, antihistamines, anti-inflammatory agents, anti-migraine preparations, antineetomy preparations, antinausea, antineoplastics, antiparkinson drugs, antipruritics, antipsychotics, antipyretics, anticholinergics, benzodiazepine antasts, vasodilators, what in gene These include coronary, peripheral and cerebral agents, bone stimulation, central nervous system stimulants, hormones, hypnotics, immunosuppressants, muscle relaxants, parasympatholytic agents, parasympathomimetics, prostaglandins, proteins, peptides, polypeptides and other macromolecules, psychostimulants, sedatives, and hypofunction. sexual and tranquilizers.
Johne's Disease Paratuberculosis (Johne's disease) is a chronic, progressive and enteric disease of ruminants caused by infection with Mycobacterium for tuberculosis. Symptoms of the disease in infected animals include weight loss, diarrhea, and decreased milk production in cows. The prevalence of Johne disease in cattle is estimated at 22-40% and the economic impact of this disease in the dairy industry was estimated at more than $ 200 million per year in 1996. In addition, the M. for tuberculosis has been implicated as a causative factor of Crohn's disease, a chronic inflammatory bowel disease in humans, which has served as an additional boost to control this disease in our national cattle industry. The treatment and prevention of Johne's disease has made it a high priority disease in the cattle industry. Membrane protein p34, SEQ ID No IA, elicits the predominant humoral response against M. for tuberculosis and within the published sequence the antigenic peptide epitopes have been identified, including but not limited to: NYESQPGGQPNT (SEQ ID No 1) QYTDHHSSLLGP (SEC ID No 2) LYRPSDSSLAGP (SEQ ID No. 3) See for example, Ostro ski, M et al. (2003) Scandinavian Journal of Immunology, 58, 511-521. Peptide regions in other potential antigens can also be used in the device which can include the antigens described in: Hydroperoxide Reductases C and D Bishop which are major antigens constitutively expressed by Mycobacterium um avi um subsp. of paratuberculosis. Olsen, et al. (2000) Infection and immunity, 68 (2), 801-808. Two pi 1 and p 20 proteins have been identified as potential antigens to be used in vaccination. Thus, properly nanostructured vaccines for Mycobacterium um infection for diseases such as Johnes disease can be made and delivered according to the method and device of the present invention.
Bovine mastitis Bovine mastitis is a serious problem, common in lactating animals of both dairy and bovine types. The treatment for this disease is practiced mainly in the dairy type animal where it is required to handle udders daily. Mechanical milking machines may have caused an increased incidence of mastitis; The true origins of the disease remain unknown. The bacterial organisms that are identified in affected glands are varied; however, the species of Streptococcus and Staphlococcus are the most commonly isolated. Purified proteins that act as antigens for bovine mastitis have also been described and incorporated by reference; Immunization of dairy cattle with recombinant Streptococcus uberis GapC or a CAMP chimeric antigen provides protection against heterologous bacterial challenge. Fontaine et al. (2002) Vaccine, 2278-2286. It is expected that the specific peptide epitopes of these proteins would be antigenic. The PauA protein has been successfully used to vaccinate cattle to prevent mastitis caused by S challenge infection. uberis (Leigh, J. A. 1999. "Streptococcus uberis: a permanent barrier to the control of bovine mastitis?" Vet. J. 157: 225-238). Vaccinated, protected cattle generated serum antibody responses that inhibited plasminogen activation by PauA. , PauA protein sequence S. uberis: MKKWFLILMLLGIFGCATQPSKVAAITGYDSDYYARYIDPDENKITFAINVDGFVEGSN QEILIRGIHHVLTDQNQKIVTKAELLDAIRHQMVLLQLDYSYELVDFAPDAQLLTQDRR LLFANQNFEESVSLEDTIQEYLLKGHVILRKRVEEPITHPTETAMEYKVQFATKDGEFH PLPIFVDYGEKHIGEKLTSDEFRKIAEEKLLQLYPDYMIDQKEYTIIKHNSLGQLPRYY S YQDHFSYEIQDRQRIMAKDPKSGKELGETQSIDNVFEKYLITKKSYKP (SEQ ID No 4) The peptides of the epitope region are selected from this protein are useful as vaccine candidates when presented in the form of appropriate nanoparticle: that includes but is not restricted to ILIRGIHHVL (SEC ID No 5) IRHQMVLLQL (SEC ID No 6) As well as the complete or selected fragments of the above-mentioned protein sequence.
Meningococcal disease The Omp85 proteins of the Neisseria gonorrhoeae and
N. meningi tides and the peptide sequences that are derived therefrom can be used as vaccines against the organisms that cause meningococcal disease when they occur in nanoparticle form or variants, according to EU 2005074458, which is incorporated herein invention by reference. And the gonococcal and opacity proteins according to EP0273116, which include but are not restricted to: GRGPYVQADLAYAYEHITHDYP (SEQ ID No. 7) STVSDYFRNIRTHSIHPRVSVGYDFGG RIAADYARYRK NDNKYSV (SEQ ID NO 8) and its variants.
Hepatitis C Virus Fragments of the core protein used for in vitro immunization may include but are not limited to: QDVKFPGGGVYLLPRRGPRL (SEC ID No 9) RRGPRLGVRATRKTSERSQPRGRRQ (SEC ID No 10) PGYPWPLYGNEGCG AGWLLSPRGS (SEC ID No 11) These are can be used in conjunction with or without Toll and / or lipoprotein receptors as indicated in the following reference: Cell activation by synthetic lipopeptides of hepatitis C virus (HCV) - the core protein is mediated by similar receptors toll (TLRs) 2 and 4.
Hepatic Dysoma Liver fluke (Fasciola spp.) Infects a wide variety of animals, including humans. The disease that is caused is known as Fasciolosis. As with most parasitic diseases, it has a complex life cycle. Economically, sheep and cattle are of primary importance. Infection with liver fluke leads to decreased production due to poor energy conversion (meat and milk in cattle, meat and wool in sheep) and can lead to mortality (particularly in sheep). Targeted vaccines for the liver fluke have been investigated for many years, most subunit vaccines focusing on glutathione S-transferase (GST), cathepsin L (catL) and fatty acid binding proteins (FABP). Attenuated vaccines, which are created by metacercaria irradiation, are very effective, however this method of vaccination is not commercially viable. Therefore, candidates for subunit vaccines have been considered. DNA vaccines and recombinant proteins such as cathepsin B have been cloned and analyzed. Antigens and the use of cathepsin L proteases have been cloned as the vaccines described, see for example EU Patents No. 6,623,735 and 20050208063, which are incorporated herein by reference. The N-terminal sequences of the proteases to be used for in vitro immunization may include but are not limited to: AVPDKIDPRBSG (SEQ ID NO: 12) These may be incorporated into a nanoparticle (s) or may be formed as a nanoparticle .
Injectable nanoparticles An injectable nanoparticle can be prepared with that which includes a substance that is delivered and a nanoparticular polymer that covalently limits with the molecule (s), where the nanoparticle is prepared in such a way that the molecule delivery (s) ) is carried out on the outer surface of the particle. Nanostructured molecules injectable for example with antibodies or fragments of antibodies on their surfaces can be used to target specific cells or organs as preferred for the selective dosing of drugs. The molecule to be delivered can covalently limit the nanoparticular polymer by reaction with a terminal functional group, such as the hydroxyl group of a poly (alkylene glycol) nanoparticle by any method known to those skilled in the art. For example, the hydroxyl group can react with a terminal carboxyl group or amino terminal group on the molecule or antibodies or antibody fragment, to form an ester or amide bond, respectively. Alternatively, the molecule can be linked to poly (alkylene glycol) through a dysfunctional space group such as diamine or dicarboxylic acid, which include but are not limited to sebacic acid, adipic acid, isophthalic acid, terephthalic acid, fumaric acid, dodecanedicarboxylic acid, azelaic acid, pimelic acid, suberic acid (octanedioic acid), itaconic acid, biphenyl-4,4 '- dicarboxylic acid, benzophenone-4,4'-dicarboxylic acid, and p-carboxyphenoxyalkanoic acid. In this embodiment, the space group reacts with the hydroxyl group on the poly (alkylene glycol), and then reacts with the molecule (s). Alternatively, the space group may react with the molecule, such as an antibody or antibody fragment, and then react with the hydroxyl group on the poly (alkylene glycol). The reaction should be carried out under conditions that do not adversely affect the biological activity of the molecule that adheres covalently to the nanoparticle. For example, those conditions that cause the denaturation of proteins or peptides, such as high temperature, certain organic solvents and solutions of high ionic strength, should be avoided when a protein is bound to the particle. For example, organic solvents can be removed from the reaction system and a water-soluble coupling reagent such as EDC used instead. According to another embodiment, the agent that is delivered can be incorporated into the polymer acting as a nanoparticle formation. Substances to be incorporated should not chemically interact with the polymer during manufacture, or during the release process. Additives such as inorganic salts, BSA (bovine serum albumin), and inert organic compounds can be used to alter the release profile of the substance, as is known to those skilled in the art. Biologically labile materials, for example, prokaryotic or eukaryotic cells, such as bacteria, yeast, or mammalian cells, including human cells, or components thereof, such as cell walls, or cellular conjugates, may also be included in the particle. The injectable particles that are prepared according to this process can be used to deliver drugs such as non-steroidal anti-inflammatory compounds, anesthetics, chemotherapeutic agents, immunotoxins, immunosuppressive agents, steroids, antibiotics, antivirals, antifungals, and spheroidal anti-inflammatories, anticoagulants. For example, hydrophobic drugs such as lidocaine or tetracaine can be entrapped in the injectable particles and released for several hours. Charges in nanoparticles as high as 40% (by weight) can be achieved. Hydrophobic materials are more difficult to encapsulate, and in general, the loading efficiency decreases over that of a hydrophilic material. In one embodiment, an antigen is incorporated into the nanoparticle, alternatively, the antigen can make up the nanoparticle in its entirety. The term "antigen" includes any chemical structure that stimulates the formation of antibodies or elicits a cellular mediated humoral response, including but not limited to protein, polysaccharide, nucleoprotein, lipoprotein, synthetic polypeptide, or a small molecule (hapten) linked to a protein carrier. The antigen can be administered together with an adjuvant as preferred. Examples of suitable adjuvants include synthetic glycopeptides, muramyl dipeptide. Other adjuvants include Bordetella pertussis dead, the liposaccharide of Gram-negative bacteria, and large polymeric anions such as dextran sulfate. A polymer, such as a polyelectrolyte, can also be selected for the manufacture of the nanoparticle that provides adjuvant activity. Specific antigens that can be loaded into the nanoparticles described herein include, but are not limited to, attenuated or killed viruses, toxoids, polysaccharides, cell wall or surface or virus and bacteria coating proteins. These can also be used in combination with conjugates, coadjuvants, or other antigens. For example, Haemophilius influenzae in the form of purified capsular polysaccharide (Hib) can be used alone or as a conjugate with diphtheria toxoids. Examples of organisms from which these antigens are derived include poliovirus, rotavirus, hepatitis A3 B, and C, influenza, rabies, HIV, measles, mumps, rubella, Bordetella pertussus, Streptococcus pneumoniae, Clostridium diptheria, C. tetani, Vibrio cholera, Salmonella spp. , Neisseria spp. , and Shigella spp. . The nanoparticle must contain the substance that is delivered in an amount sufficient to deliver to a patient an amount of therapeutically effective compound, without causing serious toxic effects in the patient being treated. The desired concentration of active compound in the nanoparticle will depend on the rates of absorption, inactivation, and excretion of the drug as well as the rate of delivery of the compound from the nanoparticle. It will be noted that the dose values will also vary depending on the severity of the condition to be alleviated. It will further be understood that for any particular subject, the specific dose regimens should be adjusted over time according to the individual need and professional judgment of the person administering or supervising the administration of the compositions. Now, the present invention will be more fully described with reference to the appended examples. It will be understood, however, that the description below is for illustrative purposes only and should not be taken in any way as a restriction on the generalities of the present invention described above.
EXAMPLE 1 Formation of a mold using a polycarbonate sheet
Laser ablation A polycarbonate sheet is ablated by laser using an excimer laser beam. The cross section of the needle is determined by the shape of the aperture through which the laser beam passes before the polycarbonate workpiece is irradiated. This process, known as excimer laser photolithographic ablation, uses an imaging lens to form the desired shapes. The depth of the laser ablation, and therefore the maximum height of the mold material, are determined by a computer program that operates the excimer micromachining system. Using the excimer laser ablation of a polycarbonate sheet, a series of molds for microneedle arrays with eleven different shapes and heights and of a variety between 20μm and 200μm were manufactured. The molds were manufactured for a number of different forms of microneedles including square, circular, oval, cross needle, triangular, chevron, serrated chevron and half moon. In addition to the shape of the micro-needle, the density, depth and degree of inclination of the microneedle were varied. For example, the laser ablation process was used to create molds for two dense arrays: a) forms with 50μm diameter with a degree of inclination of 50μm and approx. lOOμm in height. b) shapes with 100 μm diameter with a degree of inclination of 100 μm and approx. 100 μm in height. The molds were evaluated to determine their suitability for the manufacturing process with a variety of techniques including optical microscopy, laser scanning, confocal microscopy and electron scanning microscopy. In our experience, structures with good perforations are usually complex in cross sections, and not normal simple conical protrusions. Therefore, the shapes were chosen among those that contain characteristics and symmetry of edges such that they lead to improve the performance of perforations.
EXAMPLE 2 Fabrication of microneedle arrays The first molding tests were carried out with materials with two different viscosities. The more viscous material had a consistency similar to a putty, the second had a viscosity similar to honey. These materials were applied to the polycarbonate molds and pressure was applied by means of a glass tile to ensure that the indentations were filled. To assist in the removal of gas bubbles in the molds, vacuum was applied to the molding materials. The material was hardened by curing the polymer / polymer precursor using a sixty-second exposure to light from a portable source of blue LED through the glass tile. The extraction of the mold was a simple process, relying on the tendency of the material to a greater adhesion to the back of the glass tile more than to the polycarbonate mold. The molds were made with polycarbonate sheet with 250 to 500 μm thickness and were more flexible than glass tile. Therefore the molded material could be "peeled off" from the more slightly flexible mold. The resulting structures were examined under an optical microscope. Some of the structures were measured using a confocal laser scanning microscope or projected using a scanning electron microscope.
Results The second honey-like material filled the mold, and the air bubbles that formed in the needle in the nooks and crannies of the mold were eliminated through the application of vacuum. Many of the structures were successfully removed from the mold and the mold was recovered for future tests with a combination of liquid and sonication. A silicone releasing agent was applied to the polycarbonate to assist in the extraction of the mold, alternatively, materials such as PEEK or silicone elastomers can be used as concave molds.
EXAMPLE 3 Manufacture of various microneedle arrays A number of micro-needle arrays were manufactured with variation in shape, length, aspect ratios and needle densities. The various forms are shown in figure 1.
i) Cross-shaped needle approximately 170μm in height Cross-shaped needle molds filled well with polymer, including the point at the intersection of the cross that is formed as a result of the ablation process. The combination of the relatively large lateral arms and the fine characteristic at the apex produces a robust structure with good mechanical properties. i) Circular microneedle with 50μm diameter The circular microneedle was produced approximately 140μm in height with an approximate aspect ratio of 3.
ii) Triangular microneedle 50μm per side A triangular microneedle was prepared with approximately 100 μm height and an aspect ratio of approximately 2. The smooth apex of the shape is due to the polymer molding material and does not fully reproduce the fine texture of the ablation mold.
iii) Circular microneedles Arrangement patches were produced with circular microneedles 20 μm in diameter and 50 μm in height and 100 μm in diameter with a degree of inclination of 100 μm, and approximately 100 μm in height. v) Oval shapes, cheiron, chevron toothed, triangle, crescent and diamond A variety of different needle-shaped profiles were produced to investigate the effect of perforation on the skin of the microneedle shape.
EXAMPLE 4 Fabrication of patch patches with spikes and color crossings Patch patches were constructed with a series of colored tips and crosses with polydimethylsiloxane (PDMS), a clear elastomer material by excimer laser machining 2 polycarbonate molds with four patches of 10 mm x 10 mm each, with concave features of circular reduction structures, and crosses. The degree of inclination and depth of the structures were varied. Clear and color PDMS were projected from these characteristics. The first modeling tests were conducted with standard PDMS supplied by DUPONT. This is a two-part formulation, adding 10% accelerator to cause the material to set. The mixture was placed in a vacuum chamber to accelerate degassing before molding to prevent bubble formation during curing. Figure 2 shows a top view of the manufactured cross-shaped microneedles PDMS and Figure 3 shows the side view of the manufactured cross-shaped microneedles. Figures 4, 5 and 6 show various microneedle arrays prepared according to the methods described. An aqueous based dye was added to the PDMS before molding; the addition of large amounts of dye intensifies the color, additional hardening accelerator was added to compensate for the volume of added aqueous dye. The material was hardened by curing the molded material by placing it in an oven at 45 ° C for several hours. The cure rate was significantly slower for the material with color. Surprisingly upon leaving the mold the water-colored material was more successful than the colorless material. This may be due to a variety of effects such as that of the hardening accelerator, molding with thicker parts that tend to be held within the needles more effectively during the extraction of the mold, or perhaps some inhibition of adhesion between the PDMS and the polycarbonate as a result of the aqueous additive.
EXAMPLE 5 Post-cure modification of the microneedle arrays The microneedles that were produced with the method of Example 3 can be coated with a layer of a biocompatible electrically conductive polymer to modify delivery characteristics of the microneedle. In this way, to assist in the delivery of certain types of molecules, a polyaniline coating can be applied to the solid polymeric microneedle after leaving the mold. The conductive polymer can be employed using techniques known in the art, including electrodeposition. During the electrodeposition phase (which includes polymerization) the biological reagents (for vaccines, drug delivery, etc.) can be included in the conductive polymer. The conductive polymer can be polymerized (electrodeposited) under conditions such that the surface of the electrodeposited polymer has characteristics that allow diffusion of the biological reagent to the outside in the surrounding environment
(skin) so that the biological reagent is functional for its purpose. A different number of coatings can be produced. Thicknesses can be employed depending on the desired application, ranging from 20 nm to 20 μm. In another experiment, polyaniline and polypyrrole can be co-deposited electrochemically in microneedles made of conductive materials under potentiostatic or galvanostatic conditions. The electropolymerization can be carried out by varying the applied potential and the feed rate of the monomers. The formation of polyaniline-polypyrrole compound coatings can be confirmed by the presence of characteristic peaks in polyaniline and polypyrrole in the infrared spectrum. The coatings composed of polyaniline and polypyrrole can be formed in the applied potentials of < 1.0 V. Polypyrrole is preferably formed at 1.5 V. Electrodeposition methods have been previously described and include Adeloju, S.B. and Shaw, S. J., (1993) "Potentiometric biosensor with polypyrrole base for urea" Analytica Cimica Actica, 281, pages 611-620; Adeloju S.B. and La al, A., (2005) Intern. J. Anal. Chem. , 85, pages 771-780, based on its use as a sensor. We have surprisingly discovered that the techniques can be used for the incorporation of proteins and peptides in a polymer layer to deliver proteins and peptides as a therapeutic as well as peptide and protein antigens (for vaccines), hormones (erythropoietin, parathyroid hormone) and drugs (insulin)
EXAMPLE 6 Delivery Nanoparticles Nanoparticles can be formed with metals
(gold silver) light metals, polymer material by any of the standard techniques (U.S. Patent No. 6,908,496 Halas et al; U.S. Pat. No. 6, 906, 339 Dutta; U.S. Pat. No. 6,855,426 Yadav; U.S. Pat. No. 6,893,493 to Cho et al.). The surface of the nanoparticles can be functionalized to anchor / immobilize (multimerize) the biological reagents to improve the efficacy of the immunization. Other examples without limitations of methods for the formation of nanoparticles include: Cao L, Zhu T and Liu Z (2005) "The formation of a mechanism of non-spherical gold particles during inoculation growth: function of adsorption of anion and speed of reduction . " Colloid Interface Science Journal, July 11. Bilati U, Alleman E and Doelker E. (2005) "Poly (D, L-lactide-co-glycolide) nanoparticles with protein loading prepared by means of the double emulsion method - Processing and formulation issues to increase adhesion efficiency. " Microencapsulation Journal, 22 (2), 205-214. Rolland JP, Maynor BW, Euliss LE, Exner AE,
Denison GM and Desimone JM (2005) "Direct manufacturing and collection of monodisperse nanobiomaterials, specifically." Journal of the American Chemical Society, 127 (28), 10096-100. Biological agents can be immobilized on the surface of a nanoparticle or integrally incorporated into the nanoparticle during manufacture. The delivery agent can even be directly manufactured or naturally presented in a nanoparticular form. The biological agents insulin and ovalbumin were structured as nanoparticles using supercritical fluid technology, to produce nanoparticles of dimensions 50-300 nm. The insulin nanoparticles were suspended in a solvent (ethanol) and adhered to the surface of the microneedles. The insulin and ovalbumin that adhered to the microneedles are each delivered separately through the stratum corneum and the response to insulin delivery can be measured. Erythropoietin is a glycoprotein hormone that is produced in the liver during fetal life and in the kidneys of adults and is involved in the maturation of erythroid progenitor cells in erythrocytes. There are several human conditions and treatments for cancer which results in low levels of circulating red blood cells and therefore the administration of erythropoietin is preferred. The erythropoietin can be nanostructured by means of supercritical fluid technology and added to the microneedles to be delivered by means of a microneedle array, and the efficiency of delivery can be measured by the physiological effects on the number of red blood cells in mice (including flow cytometry). EXAMPLE 7 Nanoparticles for the creation of nanopores in array patch microneedles The surface of a polymeric microneedle array can be nanostructured during fabrication by means of a microneedle liner that is molded with nanoparticles that can be removed selectively. The microneedles can then be molded, hardened and extracted from the mold to produce microneedles with nanoparticles that adhere to the surface of the microneedles. The adhered nanoparticles can then be removed, for example by dissolution or extraction techniques, to produce a microneedle having nanosize pores or cavities on its surface. The molecules or nanoparticles of the delivery agent can then be associated with the introduced pores by means of non-covalent interactions or covalent bonds. With respect to the process shown in Figure 7, the method includes the steps of: (i) "Stenciling" the soluble nanoparticles that are incorporated into microneedles during the manufacture of patches;
(ii) Place in the template the nanoparticles that are removed with solvent leaving recesses on the surface of the microneedle and then add nanostructured reagent (s) to the solution; (iii) The nanostructured reagent (s) fit within the recesses within the needle structure to form the microneedles with the nanostructured reagents that are associated with the microneedles. The molded microneedle can alternatively be chemically treated with a solvent, chemical reagent, electrochemical or physical treatment to induce the surface cavity and / or nanopore formation.
EXAMPLE 8 Microneedles made of electrically conductive polymers A polyaniline microneedle array can be manufactured by electropolymerizing a monomer solution contained in a microneedle array mold under an applied potential. The progress of electropolymerization can be monitored by weight gain analysis and infrared spectroscopy. The nanoparticles can be added to the monomer solution before polymerization to form a microneedle array with the delivery molecule integrally incorporated into the needles, or the nanoparticles can be associated with the surface of the microneedles by means of a subsequent step to the output of the mold.
EXAMPLE 9 Coating of quantum dots in microneedle arrays To demonstrate the efficiency of nanoparticle patch loads, a series of microneedle arrays were coated with quantum dots. The quantum dots are semiconductor crystals typically between 1 and 10 nm in diameter and have unique properties between those simple molecules and bulk materials. Under the influence of an external source of electromagnetic radiation, quantum dots can be made fluorescent and thus determine their precise position using readily available optical techniques. Circular microneedle fixation patches with ammunition-shaped needles and cross with PLGA (Poly-DL-glycolic lactic acid, 0.8 cm in diameter with a 2 mm edge) were constructed. The patches were coated with quantum dots by placing 100 μL of CdSe / ZnS quantum dots (200 picoMolar, Invitrogen Qtracker ™ 655 nm) on the microneedles and air-dried. The arrays were examined with fluorescence using confocal microscopy.
The arrangements showed red fluorescence in the needles in the form of ammunition and cross indicating coating by the quantum dots. As shown in Figure 7, the coverage was shown at the top of the needles and under the sides towards the base. The cross-shaped needles demonstrated a more confluent coverage of the quantum dots, as shown in Figure 8. Absorption of quantum dots by lymphocytes can be observed through in vitro studies on cultured cells and in vivo studies on hairless mouse models.
EXAMPLE 10 Coating of insulin nanoparticles in microneedle arrays To demonstrate the efficiency of patch loads with nanoparticular biological molecules, a series of microneedle array patches were coated with nanostructured insulin. Insulin can be nanostructured using various methods that include supercritical fluid technologies. The size of the insulin particle is on average 300 nm. High-density PLGA circular patches and needle forms were coated with nanostructured insulin by placing 100 μL of nanostructured insulin in isoamyl alcohol (total 0.6 insulin units / patch) on the patches and air-dried. The patches were then examined for the presence of insulin using scanning electron microscope with field emission cannon (FEG-SEM), as shown in Figures 9 and 10. The patches demonstrated the presence of nanostructured insulin on both upper surfaces of the microneedles and under the side edges of the needles. The density of the insulin nanoparticles in the cross-shaped microneedles was smaller due to the larger surface area of the crosses compared to the ammunition.
EXAMPLE 11 Demonstration of skin penetration and delivery of quantum dots The ammunition-shaped patches were coated with quantum dots by placing 100 μL of CdSe / ZnS quantum dots (200 picoMolar in serum, Invitrogen Qtracker ™ 655nm) on the microneedles and dried on air. The patches were applied to the hind flank of nude mice by means of manual pressure. The patch was removed and the skin excised and examined with fluorescence using confocal microscopy, as shown in Figure 11. The skin showed red fluorescence on the surface of the stratum corneum indicating deposition of the quantum dot present at the base of the array. A deeper confocal image within the epidermis indicated red fluorescence in the form of an ammunition demonstrating the penetration of the microneedle to a total depth of approximately 60 μm, as shown in Figure 12. This experiment conclusively demonstrates that the arrangement of Microneedle can be used to deliver nanoparticles through a layer of the stratum corneum of the dermis.
EXAMPLE 12 Delivery of nanostructured insulin using arrangement microparches
Preparation of insulin nanoparticles Insulin was nanostructured using a supercritical fluid process. An average particle size of 300 nm was obtained. The insulin was suspended in several solvents including isopropanol, isoamyl ethanol, ethanol, methanol or other coatings within the array. To coat the microarrays, insulin nanoparticles were suspended in solvent for a final concentration of 120 U / ml (4.32 mg / ml) and subjected to sonication for 60 seconds to ensure complete dispersion through the suspension. The suspension was then applied to each microarray (6U in 50 μl) and air drying was allowed. For subcutaneous delivery in the control experiments, the solution that was used to coat the microarrays was diluted 1: 300 in normal serum (final concentration 0.4U / ml).
Blood Glucose Experiments Hairless mice were anesthetized with pentobarbitone (60 mg / kg, Lp.). Blood samples were obtained by tail laceration and blood glucose was measured using a commercial glucose meter (Optimum ™ Xceed ™; Abbot Diagnostics). After obtaining two consecutive readings, the mice were treated as indicated and the blood glucose was recorded every 20 minutes for the recording of the experiment.
The mice were treated with a positive control
(insulin suspension, lU / kg, s.c.), microarrays loaded with insulin (2 patches per mouse, 6U / patch), or negative control (12U of insulin applied directly to the skin without any microarray). The administration of insulin by means of a micropatch of arrangement can be observed in the mouse by a change in glucose in blood levels. Any analysis of the documents, records, materials, devices, articles or the like that have been included in the present specification are only for purposes of providing a context for the present invention. It is not considered an acknowledgment that any or all of these materials form part of the prior bases of the art or are of general common knowledge in the field pertaining to the present invention had they existed prior to the priority date of each of the claims of this application. It will be appreciated by persons skilled in the art that numerous variations and / or modifications to the present invention can be made as shown in the specific embodiments without departing from the spirit or scope of the present invention as broadly described. The present modalities are, therefore, to be considered in all respects as illustrative and not restrictive.
Claims (73)
1. - A device suitable for delivering at least one nanoparticle comprising a microneedle having at least one nanoparticle that is associated with at least part of a surface of the microneedle and / or at least part of the tissue of the microneedle.
2. The device according to claim 1, characterized in that the device has at least two microneedles.
3. The device according to claim 2, characterized in that the microneedles are arranged without pattern, arrangement or other such configuration.
4. The device according to any of the preceding claims, characterized in that the nanoparticle (s) is associated with at least a part of the outer surface of the microneedle.
5. The device according to any of the preceding claims, characterized in that the nanoparticle (s) is associated with pores on the surface of the microneedles.
6. The device according to any of the preceding claims, characterized in that the nanoparticle (s) is associated with at least a part of the tissue of the microneedle.
7. The device according to claim 1, characterized in that the nanoparticle (s) is associated with all the tissue of the microneedle.
8. The device according to claim 6, characterized in that the nanoparticle (s) is associated with internal pores in the tissue of the microneedle.
9. The device according to any of the preceding claims, characterized in that the association comprises a non-covalent interaction that is selected from any or any of the group comprising ionic bonds, hydrophobic interactions, hydrogen bonds, Van der Waals forces or dipole-dipole links.
10. The device according to any of claims 1 to 8, characterized in that the association is made by means of a covalent bond to a functional group in the microneedle.
11. The device according to claim 10, characterized in that the functional group (s) is (are) selected from the group comprising COOR5 CONR2, NH ?, SH, and OH, wherein R comprises H; organic or inorganic chain.
12. The device according to any of the preceding claims, characterized in that the microneedle (s) is manufactured (n) of a porous or non-porous material that is selected from the group comprising metals, natural or synthetic polymers, glasses, ceramics, or combinations of two or more of them.
13. The device according to claim 10, characterized in that the microneedle (s) is manufactured from a polymer selected from the group comprising: polyglycolic acid / polylactic acid, polycaprolactone, polyhydroxybutyrate-valerate, polyorthoester, and polyethylene oxide / polybutylene terephthalate, polyurethane, polymers of silicone, and polyethylene terephthalate, polyamine plus a trilayer of dextran sulfate, poly-L-lactic acid of high molecular weight, fibrin, methylmethacrylate (MMA) (hydrophobic, 70 mol% ) and 2-hydroxyethyl methacrylate - (HEMA) (hydrophilic 30 mol%), poly (ester-amide) elastomeric polymers (co-PEA), polyetheretherketone, (Peek-Optima), biocompatible thermoplastic polymer; conductive polymers, polystyrene or combinations of two or more thereof.
14. The device according to any of the preceding claims, characterized in that the microneedle (s) includes a layer or coating on at least a part of the surface of the microneedle (s) of a material electrically conductive
15. The device according to claim 14, characterized in that the electrically conductive material is selected from the group comprising conductive polymers; Compound conductive materials; doped polymers, conductive metallic materials or combinations of two or more thereof.
16. The device according to claim 15, characterized in that the conductive polymer is selected from the group comprising substitutable or irreplaceable polymers comprising polyaniline; polypyrrole; polysilicones; poly (3, -ethylenedioxythiophene); polymer doped with carbon nanotubes; polymers doped with metal nanoparticles, or combinations of two or more thereof.
17. The device according to any of claims 14 to 16, characterized in that the thickness of the layer or coating is from about 20 nm to about 20 μm.
18. - The device according to any of claims 14 to 17, characterized in that the electrically conductive material is layered or coated on the microneedle (s) by electrodeposition.
19. The device according to any of claims 14 to 18, characterized in that at least one nanoparticle is contained in the electrically conductive material.
20. The device according to any of the preceding claims, characterized in that the nanoparticle (s) is delivered to an organism and the microneedle (s) is made of a biocompatible material.
21. The device according to any of the preceding claims, characterized in that the microneedle (s) is not / are biodegradable (s).
22. The device according to any of the preceding claims, characterized in that the or each microneedle is solid.
23. The device according to any of the preceding claims, characterized in that the nanoparticle (s) is / are an active agent (s).
24. The device according to any of the preceding claims, characterized in that the nanoparticle (s) is / are a carrier (s).
25. The device according to claim 24, characterized in that the nanoparticle is associated with an active agent.
26. The device according to claim 25, characterized in that the active agent (s) is associated with the nanoparticle (s) by means of a covalent or non-covalent bond.
27. The device according to claim 25 or claim 26, characterized in that the nanoparticle encapsulates the active agent.
28. The device according to claim 25 or claim 26, characterized in that the active agent is incorporated in the nanoparticle (s).
29. The device according to any of claims 26 to 29, characterized in that the nanoparticle (s) is manufactured from a material that is selected from the group comprising metals, semiconductors, inorganic or organic polymers, magnetic colloidal materials, or combinations of two or more thereof.
30. The device according to claim 29, characterized in that the metal is selected from the group comprising gold, silver, nickel, copper, titanium, platinum, palladium and its oxides or combinations of two or more thereof.
31. The device according to claim 29, characterized in that the polymer is selected from the group comprising a conductive polymer; a hydrogel; agarose; polyglycolic acid / polylactic acid; polycaprolactone; polyhydroxybutyrate-valerate; poliortoester; polyethylene oxide / polybutylene terephthalate; polyurethane; polymeric silicon compounds; polyethylene terephthalate; polyamine plus a trilayer of dextran sulfate; high molecular weight poly-L-lactic acid; fibrin; copolymers of methyl methacrylate (MMA) and 2-hydroxyethyl methacrylate (HEMA), poly (ester-amide) elastomeric polymers (co-PEA); n-butyl cyanoacrylate; polyetheretherketone; (Peek-Optima), polystyrene or combinations of two or more of them.
32. The device according to claims 23 to 31, characterized in that the active agent is a biological agent.
33. The device according to claim 32, characterized in that the biological agent is a therapeutic and / or diagnostic agent.
34. The device according to claim 33, characterized in that the therapeutic agent is selected from the group comprising peptides, proteins, carbohydrates, nucleic acid molecules, an oligonucleotide fragment (s) or DNA or RNA, lipids, organic molecules , biologically active inorganic molecules or combinations of two or more thereof.
35.- The device according to claim 33, characterized in that the therapeutic agent is a vaccine.
36.- The device according to claim 35, characterized in that the vaccine is selected from the group comprising a vector containing a nucleic acid, oligonucleotide, expression gene as a vaccine or combinations of two or more thereof.
37.- The device according to claim 35, characterized in that the vaccine is selected from proteins or peptides as vaccines for diseases that are selected from the group comprising Johnes disease, bovine mastitis, meningococcal disease or combinations of two or more of the same.
38.- The device according to claim 37, characterized in that the vaccine comprises the Johne peptide disease that is selected from the group comprising: NVESQPGGQPNT (SEQ ID No I); QYTDHHSSLLGP (SEC ID No 2); LYRPSDSSLAGP (SEC ID No 3); and / or its variants.
39.- The device according to claim 37, wherein the vaccine comprises a peptide of bovine mastitis disease selected from the group comprising: MKKWFLILMLLGIFGCATQPSKVAAITGYDSDYYARYIDPDENKITFA IN VDGFVEGSNQEILIRGIHHVLTDQNQKIVTKAELLDAIRHQMVLLQLDY SYELVDFAPDAQLLTQDRRLLFANQNFEESVSLEDTIQEYLLKGHVILRK RVEEPITHPTETANIEYKVQFATKDGEFHPLPIFVDYGEKHIGEKLTSDEF RKIAEEKLLQLYPDYMIDQKEYTIIKHNSLGQLPRYYSYQDHFSYEIQ DR QRIMAKDPKSGKELGETQSIDNVFEKYLITKKSYKP (SEC ID No 4) ILIRGIHHVL (SEC ID No 5); IRHQMVLLQL (SEC ID No 6 ); and / or its variants.
40.- The device according to claim 33, characterized in that the diagnostic agent is a detectable agent.
41. The device according to claim 40, characterized in that the detectable agent is used in an analysis.
42. The device according to any of the preceding claims, characterized in that the outer diameter of the microneedle (s) is / are about 1 μm and about 100 μm.
43. - The device according to any of the preceding claims, characterized in that the length of the microneedle (s) is / are around 20 μm and 1 mm.
44. The device according to claim 43, characterized in that the length of the microneedle (s) is / are around 20 μm and 250 μm.
45.- The device according to any of the preceding claims, characterized in that the microneedle (s) is adapted (n) to provide an insertion depth of at least about 100 to 150 μm.
46.- The device according to any of the preceding claims, characterized in that the shape of the tip of the microneedle (s) is selected from the group comprising the square, circular, oval shapes, cross needle , triangular, chevron, serrated chevron, half moon or diamond.
47.- A method for manufacturing a device for the delivery of nanoparticles, the device comprising an array of microneedles and at least one nanoparticle that is associated with at least part of a surface of the microneedle, the method comprising the steps of: (i) covering at least a part of the surface of a microneedle array that is molded with the nanoparticles; (ii) molding the microneedles; characterized in that after leaving the mold, the nanoparticles are associated with the surface of the microneedles.
48. A method for manufacturing a device for the delivery of nanoparticles, the device comprising an array of microneedles and at least one nanoparticle that is associated with the pores on the surface of the microneedle, the method comprising the steps of: i) inducing porosity on at least a portion of the surface of the microneedles; ii) associate the nanoparticles with at least a part of the pores.
49. The method according to claim 48, characterized in that the step of inducing a porosity on the surface of the microneedles comprises the steps of: i) selectively leaching the micro or nanoparticles that are incorporated to the surface of the microneedle; ii) give physical, chemical or electrochemical treatment to the surface of the microneedles.
50.- A method for manufacturing a device for the delivery of nanoparticles, the device comprising an array of microneedles and at least one nanoparticle that is associated with at least part of the tissue of the microneedle, the method comprising the steps of : molding the microneedles in the presence of the nanoparticles; characterized in that after leaving the mold, the nanoparticles are associated with at least part of the tissue of the microneedles.
51.- A method for manufacturing a device for the delivery of nanoparticles, the device comprising an array of microneedles and at least one nanoparticle that is associated with at least a portion of the outer surface of the microneedle, the method comprising the steps of: i) functionalizing at least a portion of the outer surface of the microneedles with functional groups; ii) link the nanoparticles to the introduced functional groups.
52.- The method according to claim 51, characterized in that the step of functionalizing is selected from the group comprising oxidation, reduction, substitution, crosslinking, plasma, heat treatment or combinations of two or more thereof.
53. The method according to claim 52, characterized in that the functional group (s) introduced (s) are selected from the group comprising COOR, CONR2, NH2, SH, and OH, where R comprises H or an organic or inorganic chain.
54. The method according to any of claims 47 to 53, further comprising the step of coating at least a portion of the microneedles with an electrically conductive material.
55.- The method according to claim 54, characterized in that the electrically conductive material is selected from the group comprising conductive polymer; composite conductive material; doped polymer, metallic conductive materials or compounds thereof.
56. The method according to claim 55, characterized in that the conductive polymer is selected from the group of substitutable or irreplaceable polymers comprising polyaniline; polypyrrole; polysilicone; poly (3,4-ethylenedioxythiophene); polymers doped with carbon nanotubes; or polymers doped with metal nanoparticles.
57.- The method according to any of claims 54 to 56, characterized in that the thickness of the coating is from about 20 nm to about 20 μm.
58. The method according to any of claims 55 to 57, characterized in that the conductive polymer is coated on the microneedle by electrodeposition.
59.- A device suitable for delivering at least one agent comprising a microneedle that is made of an electrically conductive polymer and / or electrically conductive composite polymer, the microneedle having at least one agent that is associated with at least part of a surface of the microneedle and / or at least part of the tissue of the microneedle.
60.- The device according to claim 59, characterized in that the device has at least two microneedles.
61.- The device according to claim 60, characterized in that the microneedles are arranged in at least one arrangement.
62.- The device according to any of claims 59 to 61, characterized in that the agent (s) is associated with at least a part of the outer surface of the microneedle.
63.- The device according to any of claims 59 to 62, characterized in that the agent (s) is associated with pores on the surface of the microneedles.
64.- The device according to any of claims 59 to 63, characterized in that the agent (s) is associated with at least a part of the tissue of the microneedle.
65. - The device according to claim 64, characterized in that the agent (s) is associated with internal pores in the tissue of the microneedle. 66.- The device according to any of claims 59 to 65, characterized in that the association comprises a covalent or a non-covalent bond. 67.- The device according to claim 66, characterized in that the association is made by means of a covalent bond to a functional group in the microneedle. 68.- The device according to claim 67, characterized in that the functional group (s) is selected from the group comprising COOR, CONR2, NH2, SH, and OH, where R comprises H; organic or inorganic chain. 69.- The device according to any of claims 49 to 68, characterized in that the electrically conductive polymer is selected from the group of substitutable or irreplaceable polymers comprising polyaniline; polypyrrole; polysilicone; poly (3,4-ethylenedioxythiophene); polymer doped with carbon nanotubes; polymer doped with metal nanoparticle particles, or combinations of two or more thereof. The device according to any of claims 49 to 68, characterized in that the agent is selected from the group comprising biological agent, nanoparticle. 71. A microneedle comprising a plurality of removable biodegradable nanoparticles and / or a degradable nanoparticle. 72.- A method for delivering at least one nanoparticle (s) to a patient, the method including the steps of contacting at least one area of the patient with at least one microneedle that is associated with at least one nanoparticle, characterized in that at least one nanoparticle is delivered to the patient. 73.- A method according to claim 72, characterized in that the microneedle is in accordance with any of claims 1 to 45, and claims 59 to 70.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2005903918 | 2005-07-25 |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2008001230A true MX2008001230A (en) | 2008-09-26 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20080312610A1 (en) | Microarray Device | |
JP5161776B2 (en) | Solid solution punch comprising drug particles and / or particles adsorbed with drugs | |
US11083881B2 (en) | Method for increasing permeability of a cellular layer of epithelial cells | |
Chen et al. | Fully embeddable chitosan microneedles as a sustained release depot for intradermal vaccination | |
WO2019094349A1 (en) | Microneedle array device, methods of manufacture and use thereof | |
CN102325563A (en) | Patch production | |
US20120089117A1 (en) | Apparatus that includes nano-sized projections and a method for manufacture thereof | |
CN101120101A (en) | Apparatus and method for transdermal delivery of multiple vaccines | |
KR101853308B1 (en) | Micro-room microstrutre and method for fabricating thereof | |
Chevala et al. | Polymeric microneedles for transdermal delivery of nanoparticles: Frontiers of formulation, sterility and stability aspects | |
KR101488397B1 (en) | Process for Preparing Microstructures by Negative Pressure and Microstructures Prepared by the Same | |
Moffatt et al. | Microneedle technology | |
MX2008001230A (en) | Microarray device | |
AU2006274490A1 (en) | Microarray device | |
KR102127123B1 (en) | Manufacturing method for micro-structure | |
Rana et al. | Microneedles for delivery of anticancer therapeutics: recent trends and technologies | |
US20220370777A1 (en) | Active microneedles for enhanced payload uptake | |
Ai et al. | Recent progress of microneedles in transdermal immunotherapy: A review | |
Veronese et al. | Drug delivery systems | |
RU2574137C2 (en) | Method for improving epithelial barrier penetration | |
Dinesh et al. | Transdermal immunization: A recent tool for immunization |